Vivos (RDGL) 10-K28 Apr 202019 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2019	Apr. 24, 2020	Jun. 28, 2019
Document And Entity Information
Entity Registrant Name	VIVOS INC
Entity Central Index Key	0001449349
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 3,483,131
Entity Common Stock, Shares Outstanding		214,421,364
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 20,381	$ 5,494
Prepaid expenses	23,492	10,992
Total Current Assets	43,873	16,486
TOTAL ASSETS	43,873	16,486
Current Liabilities:
Accounts payable and accrued expenses	511,817	795,129
Related party accounts payable	32,110	38,610
Accrued interest payable	93,249	59,646
Payroll liabilities payable	100,000	11,451
Convertible notes payable, related party, net	14,500
Convertible notes payable, net	434,886	53,824
Promissory notes payable, net of discount	100,000
Related party promissory note	237,000
Total Current Liabilities	1,523,562	958,660
Total Liabilities	1,523,562	958,660
Commitments and contingencies
STOCKHOLDERS' DEFICIT
Common stock, par value, $0.001, 950,000,000 shares authorized,184,845,821 and 163,445,736 issued and outstanding, respectively	184,846	163,446
Additional paid in capital - common stock	61,721,809	60,132,139
Accumulated deficit	(73,601,109)	(71,991,012)
Total Stockholders' Deficit	(1,479,689)	(942,174)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	43,873	16,486
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, par value	2,553	2,553
Additional paid in capital - preferred stock	8,870,626	8,870,626
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, par value	1,113	3,306
Additional paid in capital - preferred stock	665,195	1,876,768
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, par value	821
Additional paid in capital - preferred stock	$ 674,457

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	184,845,821	163,445,736
Common stock, shares outstanding	184,845,821	163,445,736
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,552,642	2,552,642
Preferred stock, shares outstanding	2,552,642	2,552,642
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,113,245	3,305,755
Preferred stock, shares outstanding	1,113,245	3,305,755
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	821,292	0
Preferred stock, shares outstanding	821,292	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues, net	$ 9,500
Cost of Goods Sold	(6,028)
Gross profit	3,472
OPERATING EXPENSES
Sales and marketing expenses		11,500
Professional fees	462,952	682,217
Reserved stock units granted		113,189
Stock based compensation	608,588	1,164,885
Payroll expenses	120,000	315,000
Research and development	67,584	104,208
General and administrative expenses	74,327	98,638
Total Operating Expenses	1,333,451	2,489,637
OPERATING LOSS	(1,329,979)	(2,489,637)
NON-OPERATING INCOME (EXPENSE)
Interest expense	(261,374)	(5,649,546)
Net gain (loss) on debt extinguishment	(18,744)	605,601
Net loss on derivative liability		(186,846)
Grant income		17,583
Total Non-Operating Income (Expenses)	(280,118)	(5,213,208)
NET LOSS BEFORE PROVISION FOR INCOME TAXES	(1,610,097)	(7,702,845)
Provision for income taxes
NET LOSS	$ (1,610,097)	$ (7,702,845)
Net loss per share - basic and diluted	$ (0.01)	$ (0.14)
Weighted average common shares outstanding - basic	175,195,600	55,501,248

Statement of Changes in Stockho

Statement of Changes in Stockholders' Deficit - USD ($)	Series A Preferred [Member]	Additional Paid-In Capital - Series A Preferred [Member]	Series B Preferred [Member]	Additional Paid-In Capital - Series B Preferred [Member]	Series C Preferred [Member]	Additional Paid-In Capital - Series C Preferred [Member]	Common Stock [Member]	Additional Paid-In Capital - Common [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,779	$ 13,547,780					$ 8,212	$ 46,465,926	$ (64,288,167)	$ (4,262,470)
Balance, shares at Dec. 31, 2017	3,778,622						8,211,902
Stock issued for: Services							$ 1	448		449
Stock issued for: Services, shares							1,250
Conversion of preferred stock into common stock	$ (575)	(3,236,164)					$ 718	3,236,021
Conversion of preferred stock into common stock, shares	(574,200)						717,750
Restricted units vested							$ 78	(78)
Restricted units vested, shares							77,500
Reserved shares for services								52,094		52,094
Options and warrants issued for services								23,766		23,766
Net income loss for the period									(901,185)	(901,185)
Balance at Mar. 31, 2018	$ 3,204	10,311,616					$ 9,009	49,778,177	(65,189,352)	(5,087,346)
Balance, shares at Mar. 31, 2018	3,204,422						9,008,402
Balance at Dec. 31, 2017	$ 3,779	13,547,780					$ 8,212	46,465,926	(64,288,167)	(4,262,470)
Balance, shares at Dec. 31, 2017	3,778,622						8,211,902
Stock issued for: Services										$ 449
Stock issued for: Services, shares										1,250
Net income loss for the period										$ (7,702,845)
Balance at Dec. 31, 2018	$ 2,553	8,870,626	$ 3,306	1,876,768			$ 163,446	60,132,139	(71,991,012)	(942,174)
Balance, shares at Dec. 31, 2018	2,552,642		3,305,755				163,445,736
Balance at Mar. 31, 2018	$ 3,204	10,311,616					$ 9,009	49,778,177	(65,189,352)	(5,087,346)
Balance, shares at Mar. 31, 2018	3,204,422						9,008,402
Conversion of preferred stock into common stock	$ (393)	(735,811)					$ 490	735,714
Conversion of preferred stock into common stock, shares	(392,467)						490,584
Restricted units vested							$ 78	(78)
Restricted units vested, shares							77,500
Reserved shares for services								32,801		32,801
Options and warrants issued for services								21,645		21,645
Stock issued for: Settlement of debt							$ 5,143	371,038		376,181
Stock issued for: Settlement of debt, shares							5,143,258
Net income loss for the period									(6,011,970)	(6,011,970)
Balance at Jun. 30, 2018	$ 2,811	9,575,805					$ 14,720	50,939,297	(71,201,322)	(10,668,689)
Balance, shares at Jun. 30, 2018	2,811,955						14,719,744
Conversion of preferred stock into common stock	$ (41)	(77,671)					$ 51	77,661
Conversion of preferred stock into common stock, shares	(41,016)						51,270
Restricted units vested							$ 78	(78)
Restricted units vested, shares							77,500
Reserved shares for services								19,514		19,514
Stock issued for: Settlement of debt							$ 74,558	2,789,922		2,864,480
Stock issued for: Settlement of debt, shares							74,558,393
Net income loss for the period									(26,912,414)	(26,912,414)
Balance at Sep. 30, 2018	$ 2,770	9,498,134					$ 89,407	53,826,316	(98,113,736)	(34,697,109)
Balance, shares at Sep. 30, 2018	2,770,939						89,406,907
Conversion of preferred stock into common stock	$ (217)	(627,508)					$ 273	627,452
Conversion of preferred stock into common stock, shares	(218,297)						272,872
Restricted units vested							$ 78	(78)
Restricted units vested, shares							77,500
Reserved shares for services								8,779		8,779
Options and warrants issued for services								1,279,675		1,279,675
Stock issued for: Cash			$ 110	54,890			$ 17,078	666,062		738,140
Stock issued for: Cash, shares			110,000				17,078,500
Stock issued for: Settlement of debt			$ 2,996	1,542,078			$ 48,827	2,346,420		3,940,321
Stock issued for: Settlement of debt, shares			2,995,755				48,827,137
Stock issued for: Accounts payable and accrued expenses			$ 200	279,800			$ 7,783	1,377,513		1,665,296
Stock issued for: Accounts payable and accrued expenses, shares			200,000				7,782,820
Net income loss for the period									26,122,724	26,122,724
Balance at Dec. 31, 2018	$ 2,553	8,870,626	$ 3,306	1,876,768			$ 163,446	60,132,139	(71,991,012)	(942,174)
Balance, shares at Dec. 31, 2018	2,552,642		3,305,755				163,445,736
Conversion of preferred stock into common stock			$ (525)	(209,163)			$ 6,553	203,135
Conversion of preferred stock into common stock, shares			(524,218)				6,552,725
Options and warrants issued for services								3,792		3,792
Stock issued for: Cash			$ 100	49,900			$ 1,250	48,750		100,000
Stock issued for: Cash, shares			100,000				1,250,000
Conversion of Series B Preferred into Series C Preferred			$ (821)	(674,457)	$ 821	674,457
Conversion of Series B Preferred into Series C Preferred, shares			(821,292)		821,292
Warrants issued with notes payable (discount)								28,721		28,721
Net income loss for the period									(236,382)	(236,382)
Balance at Mar. 31, 2019	$ 2,553	8,870,626	$ 2,060	1,043,048	$ 821	674,457	$ 171,249	60,416,537	(72,227,394)	(1,046,043)
Balance, shares at Mar. 31, 2019	2,552,642		2,060,245		821,292		171,248,461
Balance at Dec. 31, 2018	$ 2,553	8,870,626	$ 3,306	1,876,768			$ 163,446	60,132,139	(71,991,012)	(942,174)
Balance, shares at Dec. 31, 2018	2,552,642		3,305,755				163,445,736
Stock issued for: Services
Net income loss for the period										(1,610,097)
Balance at Dec. 31, 2019	$ 2,553	8,870,626	$ 1,113	665,195	$ 821	674,457	$ 184,846	61,721,809	(73,601,109)	(1,479,689)
Balance, shares at Dec. 31, 2019	2,552,642		1,113,245		821,292		184,845,821
Balance at Mar. 31, 2019	$ 2,553	8,870,626	$ 2,060	1,043,048	$ 821	674,457	$ 171,249	60,416,537	(72,227,394)	(1,046,043)
Balance, shares at Mar. 31, 2019	2,552,642		2,060,245		821,292		171,248,461
Conversion of preferred stock into common stock			$ (517)	(206,283)			$ 6,462	200,338
Conversion of preferred stock into common stock, shares			(517,000)				6,462,500
Options and warrants issued for services								2,176		2,176
Warrants issued with notes payable (discount)								12,592		12,592
Adjustment for fractional shares in reverse split
Adjustment for fractional shares in reverse split, Shares							(140)
Net income loss for the period									(200,305)	(200,305)
Balance at Jun. 30, 2019	$ 2,553	8,870,626	$ 1,543	836,765	$ 821	674,457	$ 177,711	60,631,643	(72,427,699)	(1,231,580)
Balance, shares at Jun. 30, 2019	2,552,642		1,543,245		821,292		177,710,821
Stock issued for: Services							$ 312	12,188		12,500
Stock issued for: Services, shares							312,500
Options and warrants issued for services								457,949		457,949
Stock issued for: Accounts payable and accrued expenses							$ 563	21,937		22,500
Stock issued for: Accounts payable and accrued expenses, shares							562,500
Warrants issued with notes payable (discount)								95,437		95,437
Warrants issued for extension of notes payable								25,656		25,656
Options issued for settlement of accounts payable								33,829		33,829
BCF recognized on convertible notes								59,957		59,957
Net income loss for the period									(669,372)	(669,372)
Balance at Sep. 30, 2019	$ 2,553	8,870,626	$ 1,543	836,765	$ 821	674,457	$ 178,586	61,338,596	(73,097,071)	(1,193,124)
Balance, shares at Sep. 30, 2019	2,552,642		1,543,245		821,292		178,585,821
Conversion of preferred stock into common stock			$ (430)	(171,570)			$ 5,375	166,625
Conversion of preferred stock into common stock, shares			(430,000)				5,375,000
Options and warrants issued for services								148,462		148,462
Stock issued for: Accounts payable and accrued expenses							$ 500	20,900		21,400
Stock issued for: Accounts payable and accrued expenses, shares							500,000
Warrants issued with notes payable (discount)								14,299		14,299
Options issued for settlement of accounts payable								14,812		14,812
Conversion of restricted stock units into common stock							$ 385	(385)
Conversion of restricted stock units into common stock, shres							385,000
Warrants issued in settlement of litigation								18,500		18,500
Net income loss for the period									(504,038)	(504,038)
Balance at Dec. 31, 2019	$ 2,553	$ 8,870,626	$ 1,113	$ 665,195	$ 821	$ 674,457	$ 184,846	$ 61,721,809	$ (73,601,109)	$ (1,479,689)
Balance, shares at Dec. 31, 2019	2,552,642		1,113,245		821,292		184,845,821

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CASH FLOW FROM OPERTING ACTIVIITES
Net loss	$ (1,610,097)	$ (7,702,845)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of convertible debt discount	134,034	791,928
Amortization of BCF discount	55,740
Common stock issued for services	12,500	449
Stock options and warrants for services	612,379	1,325,085
Warrants issued for interest expense	25,656
Reserved stock units issued for services		113,189
Derivatives recorded as loan fees		4,636,517
(Gain) on debt extinguishment	18,744	(605,601)
Forgiveness of debt	(34,106)
Loss on fair value of derivative liability		186,846
Changes in assets and liabilities
Prepaid expenses and other assets	(12,500)	(3,612)
Accounts payable and accrued expenses	(136,371)	(1,338)
Accounts payable and accrued expenses from related party	(6,500)	(128,178)
Payroll liabilities	88,549	466,941
Accrued interest	33,603	220,165
Total adjustments	772,984	7,002,391
Net cash used in operating activities	(837,113)	(700,454)
CASH FLOWS FROM FINANCING ACTIVITES
Proceeds from related party notes payable	237,000
Proceeds from sale of preferred stock	50,000	55,000
Proceeds from sale of common stock	50,000	683,140
Proceeds from convertible debt	500,000	50,000
Repayment of convertible notes		(200,000)
Proceeds from promissory notes - related party, net of repayments	15,000	109,491
Net cash provided by financing activities	852,000	697,631
NET INCREASE (DECREASE) IN CASH	14,887	(2,823)
CASH - BEGINNING OF PERIOD	5,494	8,317
CASH - END OF PERIOD	20,381	5,494
CASH PAID DURING THE PERIOD FOR:
Interest expense	4,000
Income taxes
SUPPLEMENTAL INFORMATION - NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of preferred stock into common stock	588,487	4,678,380
Conversion of convertible preferred B into convertible preferred C	675,278
Recognition of debt discount at inception of notes payable	151,048
Recognition of BCF discount at inception of notes payable	59,957
Common stock issued in settlement of accounts payable	43,900
Common and referred stock issued for accounts payable and accrued payroll		1,665,296
Stock options issued in settlement of accounts payable	48,643
Warrants issued for settlement of litigation	18,500
Vesting of restricted stock units		2,480
Reclassification of shareholder advances to convertible notes payable	15,000	35,212
Reclassification of accrued interest to related party notes payable and convertible notes payable		1,343
Conversion of notes payable and accrued interest into common stock		$ 7,290,473

Organization & Basis of Present

Organization & Basis of Presentation	12 Months Ended
Organization & Basis of Presentation	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization & Basis of Presentation	NOTE 1: ORGANIZATION & BASIS OF PRESENTATION Business Overview Vivos Inc. (the “ Company SMSC Our principal place of business is located at 719 Jadwin Avenue, Richland, WA 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently quoted on the OTC Pink Marketplace under the symbol “RDGL.” The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device RadioGel™ for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. The Company’s current focus is on the development of its RadioGel™ device. RadioGel™ is an injectable particle-gel, for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, one micron, yttrium-90 phosphate particles (“ Y-90 The Company’s lead brachytherapy products, including RadioGel™, incorporate patented technology developed for Battelle Memorial Institute (“ Battelle Battelle License The Company is currently focusing on obtaining approval from the Food and Drug Administration ( “FDA” In February 2014, the FDA ruled the device as not substantially equivalent due to a lack of a predicate device and it was therefore classified as a Class III device. Class III devices are generally the highest risk devices and are therefore subject to the highest level of regulatory review, control and oversight. Class III devices must typically be approved by the FDA before they are marketed. Class II devices represent lower risk devices than Class III and require fewer regulatory controls to provide reasonable assurance of the device’s safety and effectiveness. In contrast, Class I devices are deemed to be lower risk than Class II or III and are therefore subject to the least regulatory controls. The Company is currently developing test plans to address issues raised by the FDA in connection with the Company’s previous submissions regarding RadioGel™, including developing specific test plans and specific indication of use. The Company intends to request that the FDA grant approval to re-apply for de novo See also Annual Report IsoPet Solutions The Company’s IsoPet Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with three different university veterinarian hospitals on IsoPet® testing and therapy. Washington State University treated five cats for feline sarcoma and served to develop the procedures which are incorporated in our label. They concluded that the product was safe and effective in killing cancer cells. Colorado State University demonstrated the CT and PET-CT imaging of IsoPet®. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting in November 2017. The dogs were treated for canine soft tissue sarcoma. Response evaluation criteria in solid tumors (“ RECIST The testing at the University of Missouri met its objective to demonstrate the safety of IsoPet®. Using its advanced CT and PET equipment it was able to demonstrate that the dose calculations were accurate and that the injections perfused into the cell interstices and did not stay concentrated in a bolus. This results in a more homogeneous dose distribution. There was insignificant spread of Y-90 outside the points of injection demonstrating the effectiveness of the particles and the gel to localize the radiation with no spreading to the blood or other organs nor to urine or fecal material. This confirms that IsoPet® is safe for same day therapy. The effectiveness of IsoPet® for life extension was not the prime objective, but it resulted in valuable insights. Of the cases one is still cancer-free but the others eventually recurred since there was not a strong focus on treating the margins. The University of Missouri has agreed to become a regional center to administer IsoPet® therapy and will incorporate the improvements suggested by the testing program. The Company anticipates that future profits, if any, will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally. The Company intends to report the results from the IsoPet® Solutions division as a separate operating segment in accordance with GAAP. Commencing in July 2019, the Company recognized its first commercial sale of IsoPet®. A doctor brought his cat with a re-occurrent spindle cell sarcoma tumor on his face. The cat had previously received external beam therapy, but now the tumor was growing rapidly. He was given a high dose of 400Gy with heavy therapy at the margins. This sale met the revenue recognition requirements under ASC 606 as the performance obligation was satisfied. The Company completed sales for an additional four animals that received Our plan is to incorporate the data assembled from our work with Isopet® in animal therapy to support the Company’s efforts in the development of our RadioGel™ device candidate, including obtaining approval from the FDA Y-90 The Company’s lead brachytherapy products, including RadioGel™, incorporate patented technology developed for Battelle Memorial Institute (“ Battelle Battelle License Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $2.3 million annually to maintain current operating activities. The Company has completed its reverse stock split which was approved by FINRA and went effective on June 28, 2019 which will enable them to begin the process of raising capital through their Regulation A+ which was filed with the Securities and Exchange Commission (“SEC”) now that the Company has available authorized shares to issue and received approval form the SEC in November 2019. The intent is to obtain up to $3,000,000 in tranches of $250,000 over time. The Company intends to use these proceeds as follows: For the animal therapy market: ● Fund the effort to communicate the benefits of IsoPet ® ● Conduct additional clinical studies to generate more data for the veterinary community ● Subsidize some IsoPet ® ● Assist a new regional clinic with their license and certification training. For the human market: ● Enhance the pedigree of the Quality Management System. ● Complete the pre-clinical testing that has been previously defined and report the bulk of the results to the FDA in a pre-submission meeting. ● Use the feedback from that meeting to write the IDE (Investigational Device Exemption), which is required to initiate clinical trials. The Company has raised $125,280 in proceeds under this Regulation A+ in March 2020, which was in escrow until April 2020 at which time it was deposited into the Company’s accounts. The common shares for these proceeds were issued in April 2020. In addition, the Company converted their outstanding convertible notes payable of $415,000, $23,427 in accrued interest and $87,686 in an exchange premium stipulated in the note agreements into shares of common stock effective March 31, 2020. These shares were issued in April 2020, however effective as of March 31, 2020. Over the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to: (1) fund the FDA approval process and initial deployment of the brachytherapy products, and (2) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises. Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy. In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses. Based on the Company’s financial history since inception, the Company’s independent registered public accounting firm has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations. The Company has been impacted from the effects of COVID-19. The Company’s headquarters are in Northeast Washington however there focus of the animal therapy market has been the Northwestern sector of the United States, the initial epicenter of the COVID-19 outbreak in the United States. In addition to a slow down in the marketing of the services, the volatility of the stock market has contributed to a lack of funds that ordinarily may have been available to the Company. The Company is hopeful that by the end of the third quarter of 2020, they will be allowed to continue their marketing to the animal therapy market and attempt to increase the exposure to their product and generate revenue accordingly. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. As of December 31, 2019, the Company has $20,381 cash on hand. There are currently commitments to vendors for products and services purchased that will necessitate liquidation of the Company if it is unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company. The Company was able to execute the following transactions to improve their balance sheet and decrease the liabilities incurred and increase their cash flow: ● In November 2019, the Company had its Regulation A+ approved by the Securities and Exchange Commission for an offering up to 150 million shares of common stock. ● During the Company’s second and third fiscal quarters, the Company secured approximately $300,000 in convertible promissory notes. ● The Company recognized its first few sales of IsoPet ® . Assuming the Company is successful in the Company’s sales/development effort, it believes that it will be able to raise additional funds through strategic agreements or the sale of the Company’s stock to either current or new stockholders. There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these audited financial statements so as to conform to current period classifications. Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Inventory Inventory is reported at the lower of cost or market, determined using the first-in, first-out basis, or net realizable value. All inventories consisted of finished goods. The Company has no inventory for the years ended December 31, 2019 and 2018. Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2019 and 2018, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis. Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date. Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down. License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%). Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per Calendar Year 2020 $ 10,000 2021 10,000 2022 4,000 Total $ 24,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The 2020 fee was paid in January 2020. Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the years ended December 31, 2019 and 2018, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. The Company recognized revenue as they (i) identified the contracts with ach customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue generated during the year ended December 31, 2019 related to sales of product. Income from Grants and Deferred Income Government grants are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Company has chosen to recognize income from grants as it incurs costs associated with those grants, and until such time as it recognizes the grant as income those funds received will be classified as deferred income on the balance sheet. On December 22, 2017, the Company received notification that Washington State University awarded it $17,500 of grant funds from the sub-award project entitled “ Optimized Injectable Radiogels for High-dose Therapy of Non-Resectable Solid Tumors Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the years ended December 31, 2019 and 2018, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2019 and 2018, which include the following: December 31, 2019 December 31, 2018 Convertible debt 10,914,782 17,594 Preferred stock 27,372,515 44,512,740 Common stock options 34,524,580 11,318,021 Common stock warrants 31,286,847 23,052,472 Total potential dilutive securities 104,098,724 78,900,827 Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $67,584 and $104,208 research and development costs for the years ended December 31, 2019, and 2018, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the years then ended. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. There were no tradeshow expenses incurred and not expensed for the years ended December 31, 2019, and 2018, respectively. During the years ended December 31, 2019 and 2018, the Company incurred $0 and $11,500, respectively, in advertising and marketing costs. Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of materials. Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2019 and 2018. Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2019 and 2018. The Company did not have any deferred tax liability or asset on its balance sheet on December 31, 2019 and 2018. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2019 and 2018, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. The Tax Cuts and Jobs Act (the “ Act Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC Topic 718, Compensation – Stock Compensation. Under FASB ASC Topic. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. The Company has determined that no amounts had to be revalued upon adoption of this amendment. Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates Step 2 from the goodwill impairment test. When an indication of impairment was identified after performing the first step of the goodwill impairment test, Step 2 required that an entity determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) using the same procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in ASU No. 2017-04, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. An entity would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. In addition, an entity must consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. A public business entity that is a SEC filer should adopt the amendments in ASU No. 2017-04 for its annual, or any interim, good will impairment tests in fiscal years beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260).” The amendments in the update change the classification of certain equity-linked financial instruments (or embedded features) with down round features. The amendments also clarify existing disclosure requirements for equity-classified instruments. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260, Earnings Per Share, to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features would be subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption did not have a material impact on the Company’s financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements,” which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Fixed Assets

Fixed Assets	12 Months Ended
Fixed Assets	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Fixed Assets	NOTE 3: FIXED ASSETS Fixed assets consist of the following at December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Production equipment $ - $ 15,182 Less accumulated depreciation - (15,182 ) $ - $ - There is no depreciation expense for the years ended December 31, 2019 and 2018. In June 2019, the Company sold the one piece of equipment still held for $0. The basis of this piece of equipment was also $0, resulting in no gain or loss on the sale.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 4: RELATED PARTY TRANSACTIONS Related Party Convertible Notes Payable As of December 31, 2019 and 2018, the Company had the following related party convertible notes outstanding: December 31, 2019 December 31, 2018 Principal Accrued Principal Accrued September 2019 $15,000 Note, 8% interest, due January 2020 $ 15,000 $ 321 $ - $ - Other related party notes - 1,054 - 1,054 March 2017 $332,195 Note, 10% interest, due May 2017 - - - - Total Convertible Notes Payable, Net $ 15,000 $ 1,375 $ - $ 1,054 Less: Debt Discount (500 ) - - - $ 14,500 $ 1,375 $ - $ 1,054 In March 2017, the Company combined Outstanding Notes owed to a director and major stockholder, along with $51,576 of accrued interest payable, into one promissory note (the “ Related Party Note Qualified Financing The Company has outstanding accrued interest in the amount of $1,054 from old related party notes that the principal had been paid off in full. The Company from time to time receives non-interest bearing advancers from its Chief Executive Officer that are due on demand. During the year ended December 31, 2019, the Company received $20,000 in advances and repaid $5,000 of these and had $15,000 outstanding at September 24, 2019. On September 24, 2019, these advances were converted into a convertible note at 8% interest which matures January 15, 2020. Interest on this note for the period ended December 31, 2019 amounted to $321, and this amount is accrued at December 31, 2019. The Chief Executive Officer received 150,000 warrants when the advances were converted into this convertible note payable. The Company recognized a discount on the convertible note of $3,721 as a result of the warrants which are being amortized over the life of the note through January 15, 2020. The Company is in default of this note. As a result of the default, the interest rate charged was changed to 12.5% through conversion of this note in April 2020. Interest expense for the years ended December 31, 2019 and 2018 on the related party convertible notes payable amounted to $321 and $29,650, respectively. Related Party Notes Payable As of December 31, 2019 and December 31, 2018, the Company had the following related party notes outstanding: December 31, 2019 December 31, 2018 Principal Accrued Principal Accrued January 2019 $60,000 Note, 8% interest, due January 2020 $ 60,000 $ 4,472 $ - $ - March 2019 $48,000 Note, 8% interest, due March 2020 48,000 2,927 - - April 2019 $29,000 Note, 8% interest, due April 2020 29,000 1,559 - - July 2019 $50,000 Note 8% interest, due July 2020 50,000 1,956 - - November 2019 $50,000 Note 8% interest, due November 2020 50,000 393 - - Total Related Party Notes Payable, Net $ 237,000 $ 11,307 $ - $ - On January 24, 2019 the Company entered into a note payable with a trust related to one of the Company’s directors in the amount of $60,000. The note is for a one-year period which was to mature January 24, 2020 and bears interest at an annual rate of 8.00%. The Company is in default of this note. On March 27, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $48,000. The note is for a one-year period maturing March 27, 2020 and bears interest at an annual rate of 8%. The Company is in default of this note. On April 29, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $29,000. On July 5, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $50,000. The note is for a one-year period maturing July 5, 2020 and bears interest at an annual rate of 8%. On November 25, 2019 the Company entered into a note payable with a trust related to one of our directors in the amount of $50,000. The note is for a one-year period maturing November 25, 2020 and bears interest at an annual rate of 8%. Interest expense for these notes for the year ended December 31, 2019 and accrued interest at December 31, 2019 is $11,307. The Company borrowed $15,000 in March 2020 from its CEO and repaid this amount in April 2020. Related Party Payables The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s behalf. As a result of these activities the Company had related party payables of $32,110 and $38,610 as of December 31, 2019 and 2018, respectively. Preferred and Common Shares Issued to Officers and Directors During 2018, the Company issued 4,832,820 shares of common stock and warrants to purchase shares of common stock totaling 2,416,410 in settlement of accrued compensation valued at $541,276. The warrants were valued at $238,973 and the Company reflected $586,936 as a loss on conversion of debt. During 2018, the Company issued 450,000 shares of common stock in settlement of accounts payable and notes payable valued at $50,400. The Company granted 225,000 warrants in connection with this transaction and recognized a loss of $35,400 in accordance with this settlement. The Company’s Chairman converted the Series B Convertible Preferred Shares into Series C Convertible Preferred Shares and as of April 2020, the 385,302 shares that are issued in the Series C Convertible Preferred Stock are all to the Chairman. In April 2020, effective March 31, 2020, the Company converted the $15,000 convertible note payable along with $619 in accrued interest and an exchange premium of $3,124 into 694,178 shares of common stock. This was part of the Regulation A+.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
Convertible Notes Payable	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5: CONVERTIBLE NOTES PAYABLE As of December 31, 2019 and 2018, the Company had the following convertible notes outstanding: December 31, 2019 December 31, 2018 Principal Accrued Interest Principal Accrued Interest July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 39,998 $ 45,000 34,603 May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015 - 17,341 - 17,341 October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $560,913, respectively - 5,953 - 5,953 January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016 - 696 - 696 May 2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019 60,000 3,264 - - July 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,880 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,235 - - September 2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 38,000 939 - - September 2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 25,000 612 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,213 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,202 - - September 2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 37,000 833 - - December 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due March 31, 2020 50,000 - - - Penalties on notes in default 10,618 - 8,824 - Total Convertible Notes Payable, Net $ 465,618 $ 75,166 $ 53,824 $ 58,593 Less: BCF Discount (6,187 ) - - - Less: Debt Discount (24,545 ) - - - $ 434,886 $ 75,166 $ 53,824 $ 58,593 Interest expense for the years ended December 31, 2019 and 2018 on the convertible notes payable amounted to $16,563 and $187,741, respectively. The May 2017 notes totaling $3,136,506, $2,419,240 after debt discounts, had a December 2017 due date which was extended to May 2018. The November 2017 Note totaling $166,666, $92,004 after debt discount, included an Investor’s Put Option whereby if the Company’s stock was not listed on the Nasdaq or NYSE by January 31, 2018, the lender had the right to require the Company to repurchase the Note at any time after January 31, 2018 in an amount equal to 130% of the sum of the Principal plus all accrued and unpaid interest. The Investor issued notice February 2, 2018 exercising it’s Put Option and requiring the Company repurchase the Note on April 19, 2018 in the aggregate amount of $228,332. The investor may elect to cancel the repurchase notice at any time prior to receiving the repurchase payment. On October 10, 2018, the Company successfully completed the terms of the Path Forward Agreements The Company entered into a convertible note in the amount of $50,000 in July 2018 with an interest rate of 8%. This note was convertible upon a Company capital raise of at least $500,000. On October 30, 2018, the Company converted this note into 1,500,000 shares of common stock at a conversion rate of $0.112 (total of $60,000 which includes $10,000 of interest and other costs) and recognized a loss on extinguishment of $108,916 on this conversion. The Company entered into a $50,000 convertible promissory note dated May 31, 2019, that was to mature October 30, 2019. The convertible promissory note bears interest at a rate of 8%, The convertible promissory note is convertible into shares of common stock at a price of $0.032 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory note together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The $10,000 contingent exchange amount is classified as original issue discount and will be amortized over the life of the convertible promissory note. The convertible promissory noteholder received 625,000 warrants at an exercise price of $0.04 per share, that have a term of two years. The warrants were valued at $12,592 and represent a debt discount, which were amortized over the life of the convertible promissory note. The Company entered into $300,000 in convertible promissory notes in July and September 2019, that were to mature January 15, 2020. The convertible promissory notes bear interest at a rate of 8%, The convertible promissory notes are convertible into shares of common stock at a price of $0.04 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory notes together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The convertible promissory noteholders received 3,000,000 warrants at an exercise price ranging between $0.06 and $0.08 per share, that have a term of two years. The warrants were valued at $91,716 and represent a debt discount, which will be amortized over the life of the convertible promissory notes. In addition, the Company recognized a beneficial conversion feature discount to the notes of $59,957 that is being amortized over the life of the notes. For the year ended December 31, 2019, the Company recognized $53,770 in amortization of the BCF discount. The Company is in default of these notes. As a result of the default, the interest rate charged was changed to 12.5% up through the conversion of this note effective March 31, 2020. The Company entered into $50,000 in a convertible promissory note on December 31, 2019, that matures March 31, 2020. The convertible promissory notes bear interest at a rate of 8%, The convertible promissory note is convertible into shares of common stock at a price of $0.04 per share. Upon the closing of an equity financing pursuant to an effective registration statement with gross proceeds to the Company totaling at least $250,000 exclusive of any exchanges (“Qualified Financing”), the outstanding principal amount of this convertible promissory notes together with all accrued and unpaid interest shall be exchanged into such securities as are issued in the Qualified Financing at a rate of 1.20. Upon an exchange, the Payee shall be granted all rights afforded to an investor in the Qualified Financing. The convertible promissory noteholders received 625,000 warrants at an exercise price of $0.06 per share, that have a term of two years. The warrants were valued at $14,299 and represent a debt discount, which will be amortized over the life of the convertible promissory note. This note was converted effective March 31, 2020.

Promissory Notes Payable

Promissory Notes Payable	12 Months Ended
Promissory Notes Payable	Dec. 31, 2019
Debt Disclosure [Abstract]
Promissory Notes Payable	NOTE 6: PROMISSORY NOTES PAYABLE As of December 31, 2019 and December 31, 2018, the Company had the following promissory notes outstanding: December 31, 2019 December 31, 2018 Principal (net) Accrued Interest Principal (net) Accrued Interest February 2019, two promissory notes for $50,000 each (total of $100,000), maturing August 2019, extended to February 2020, at 8.00% interest (originally) and now 15% interest $ 100,000 $ 5,410 $ - - Debt discount (-) - - - Total Promissory Notes Payable, Net $ 100,000 $ 5,410 $ - $ - The Company issued two separate promissory notes on February 20, 2019 at $50,000 each (total of $100,000) that were to mature on August 20, 2019 and accrued interest at 8.00% per annum. In connection with the promissory notes, the Company issued warrants to purchase 1,250,000 shares of common stock. The Company recorded the relative fair value of the warrants as a debt discount of $28,721 and amortized the discount over the life of the note (6 months). Amortization of debt discount for the year ended December 31, 2019 was $28,721 and is recorded as interest expense on the statement of operations for the year ended December 31, 2019. On August 20, 2019, the two noteholders agreed to extend these notes another six-months to February 20, 2020, then amended again for six-months and the notes now mature August 20, 2020. In consideration for the extension, the note holders received 750,000 warrants (375,000 each) and the interest rate on the notes increased from 8% to 15% per annum. The accrued interest at August 20, 2019 of $4,000 was paid to the note holders. The interest expense on these notes for the year ended December 31, 2019 amounted to $9,410, of which $5,410 is accrued for as of December 31, 2019.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 7: INCOME TAXES The Tax Cuts and Jobs Act (the “ Act Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net deferred tax assets consist of the following components as of December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Deferred tax assets: Net operating loss carryover $ 5,890,000 $ 5,760,000 Interest expense 15,000 - Related party accrual 23,400 2,300 Capital Loss Carryover 3,400 3,400 Deferred tax liabilities Depreciation (2,100 ) (2,100 ) Valuation allowance (5,929,700 ) (5,763,600 ) Net deferred tax asset $ - $ - The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2019 and 2018 due to the following: December 31, 2019 December 31, 2018 Book income (loss) $ (338,100 ) $ (1,617,600 ) Forgiveness of debt (7,200 ) - Depreciation (1,100 ) (1,100 ) Interest expense 15,000 - Related party accrual 21,100 (108,300 ) Meals and entertainment - 300 Stock for services 2,600 100 Options expense 134,000 302,000 Non-cash interest expense 39,900 1,046,900 Other non-deductible expenses - 261,800 Valuation allowance 133,800 115,900 Income tax expense $ - $ - At December 31, 2019, the Company had net operating loss carryforwards of approximately $28,045,000. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carryforwards may be limited as to use in future years. Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. At the adoption date of January 1, 2007, the Company had no unrecognized tax benefit, which would affect the effective tax rate if recognized. The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of December 31, 2019, the Company had no accrued interest or penalties related to uncertain tax positions. The Company files income tax returns in the U.S. federal jurisdiction. The Company is located in the state of Washington and Washington state does not require the filing of income taxes. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2016.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
Stockholders' Deficit	Dec. 31, 2019
Equity [Abstract]
Stockholders' Deficit	NOTE 8: STOCKHOLDERS’ DEFICIT Common Stock The Company has 950,000,000 shares of common stock authorized, with a par value of $0.001, and as of December 31, 2019 and December 31, 2018, the Company has 184,845,821 and 163,445,736 shares issued and outstanding, respectively. On March 28, 2019, the Company’s board of directors approved a reverse 1-for-8 stock split, and a decrease in the authorized shares from 2,000,000,000 to 950,000,000. The reverse stock split went effective by FINRA on June 28, 2019. Preferred Stock As of December 31, 2019 and 2018, the Company has 20,000,000 shares of Preferred stock authorized with a par value of $0.001. The Company’s Board of Directors is authorized to provide for the issuance of shares of preferred stock in one or more series, fix or alter the designations, preferences, rights, qualifications, limitations or restrictions of the shares of each series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of such series without further vote or action by the shareholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of management without further action by the shareholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others. On October 8, 2018 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series B Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares. On March 27, 2019 the Company created out of the shares of Preferred Stock, par value $0.001 per share, of the Company, as authorized in Article IV of the Company’s Certificate of Incorporation, a series of Preferred Stock of the Company, to be named “Series C Convertible Preferred Stock,” consisting of Five Million (5,000,000) shares. Series A Convertible Preferred Stock (“Series A Convertible Preferred”) In June 2015, the Series A Certificate of Designation was filed with the Delaware Secretary of State to designate 2.5 million shares of our preferred stock as Series A Convertible Preferred. Effective March 31, 2016, the Company amended the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred of the Registrant, increasing the maximum number of shares of Series A Convertible Preferred from 2,500,000 shares to 5,000,000 shares. The following summarizes the current rights and preferences of the Series A Convertible Preferred: Liquidation Preference Dividends Conversion Series A Conversion Shares In the event the Company completes an equity or equity-based public offering, registered with the SEC, resulting in gross proceeds to the Company totaling at least $5.0 million, all issued and outstanding shares of Series A Convertible Preferred at that time will automatically convert into Series A Conversion Shares. Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series B Convertible Preferred Stock (“Series B Convertible Preferred”) In October 2018, the Series B Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series B Convertible Preferred. The following summarizes the current rights and preferences of the Series B Convertible Preferred: Liquidation Preference Dividends Conversion Series B Conversion Shares Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Series C Convertible Preferred Stock (“Series C Convertible Preferred”) In March 2019, the Series C Certificate of Designation was filed with the Delaware Secretary of State to designate 5.0 million shares of our preferred stock as Series C Convertible Preferred. The following summarizes the current rights and preferences of the Series C Convertible Preferred: Liquidation Preference Dividends Conversion Series C Conversion Shares The Series C Convertible Preferred will only be convertible at any time after the date that the Company shall have amended its Certificate of Incorporation to increase the number of shares of common stock authorized for issuance thereunder or effect a reverse stock split of the outstanding shares of common stock by a sufficient amount to permit the conversion of all Series C Convertible Preferred into shares of common stock (“ Authorized Share Approval Initial Convertibility Date Conversion Rights Redemption Voting Rights Liquidation Liquidation Certain Price and Share Adjustments a) Stock Dividends and Stock Splits b) Merger or Reorganization Common and Preferred Stock Issuances - 2019 In January 2019, the Company received $100,000 in gross proceeds resulting from the issuance to accredited investors of 1,250,000 shares of common stock, 100,000 shares of Series B Convertible Preferred and warrants to purchase 1,250,000 shares of common stock. The Company issued 18,390,225 shares of common stock in consideration for the conversion of 1,471,218 shares of Series B Convertible Preferred. The Company issued 821,292 shares of Series C Convertible Preferred in exchange for 821,292 shares of Series B Convertible Preferred. The Company issued 1,062,500 shares of common stock in a settlement of accounts payable valued at $43,900. This includes 500,000 shares to the Company’s former CEO in settlement of that litigation (see Note 9). The Company issued 312,500 shares of common stock for services rendered in connection with the raising of debt instruments valued at $12,500. The Company issued 385.000 shares of common stock in conversion of vested restricted stock units. Common and Preferred Stock Issuances - 2018 During 2018, the Company issued 1,250 shares of common stock for services valued at $449. During 2018, the Company issued 128,528,788 shares of common stock and 2,995,755 shares of Series B Convertible Preferred in conjunction with the settlement of $3,545,378 worth of convertible debt (both related and non-related) and $506,245 worth of accrued interest (both related and non-related). As part of these conversions, the Company recognized offsets of $4,823,363 for derivative liabilities and recognized a gain on extinguishment of debt of $1,694,005. During 2018, the Company issued 1,532,476 shares of common stock valued at $4,678,380 in exchange for 1,225,981 shares of Series A Convertible Preferred. During 2018, the Company issued 17,078,500 shares of common stock for cash in the amount of $683,140. During 2018, the Company issued 110,000 shares of Series B Convertible Preferred for cash in the amount of $55,000. During 2018, 7,782,820 shares of common stock and 200,000 shares of Series B Convertible Preferred were issued to officers and consultants for accrued compensation as well as to settle accounts payable and shareholder advances made during the year. The value of these shares were $1,665,285. The Company recognized a loss on extinguishment on these issuances of $1,256,972. Common Stock Options The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests. The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2017 152,813 $ 4.00-120.00 3.91 years $ - $ 1.08 Options granted 11,165,208 $ 0.11 - $ - Options exercised - $ - - $ - Options expired - $ - - $ - Balance at December 31, 2018 11,318,021 $ 0.11-120.00 - $ - $ 0.24 Options granted 23,252,809 $ 0.025 4-0.04 - $ - Options exercised - $ - - $ - Options expired (46,250 ) $ - - $ - Balance at December 31, 2019 34,524,580 $ 0.024-120.00 6.49 years $ 277,973 $ 0.08 Exercisable at December 31, 2019 34,428,955 $ 0.024-120.00 6.48 years $ 276,729 $ 0.08 In June 2019, the Company issued 382,500 stock options to consultants that vest through June 30, 2020. The grant date of these options was June 17, 2019, the date of board approval. On June 21, 2019, 46,250 stock options expired that were issued June 21, 2016. There was $6,529 expensed in 2019 and $2,176 remaining to be expensed through June 30, 2020 for these options. The Company has granted 21,000,000 stock options under the Company’s 2015 Omnibus Securities and Incentive Plan to Dr. Korenko. The granting of the stock options occurs 10 days after the approval of the Company’s recent 1 for 8 reverse stock split that occurred on June 28, 2018. The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019, and December 31, 2019); (ii) 25% upon the Company filing a patent (completed on July 1, 2019); and (iii) 25% upon the first commercial sale of IsoPet ® In September 2019, the Company granted 1,000,000 stock options in a settlement agreement for past due legal fees. The options have a ten-year life and vest immediately. These options were valued at $33,829 which offset accounts payable. The Company recognized a gain of $34,106 on this transaction which is included in the net (gain) loss on debt extinguishment in the statement of operations for the year ended December 31, 2019. In September 2019, the Company granted 500,000 stock options to a consultant for services rendered. The options have a ten-year life and vest immediately. These options were valued at $16,915. In December 2019, the Company granted 370,309 stock options to consultants for accounts payable. The options have a ten-year life and vest immediately. These options were valued at $14,812. During the years ending December 31, 2019 and 2018, the Company recognized $608,588 and $1,164,885, respectively, worth of stock based compensation related to the vesting of it stock options. Common Stock Warrants The following schedule summarizes the changes in the Company’s common stock warrants: Weighted Weighted Warrants Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2017 38,026 $ 0.14 1.19 years $ 749 $ 0.32 Warrants granted 23,043,663 $ - - $ Warrants exercised - $ - - $ Warrants expired/cancelled (29,217 ) $ - - $ Balance at December 31, 2018 23,052,472 $ 0.08-80.00 1.77 years $ - $ 0.08 Warrants granted 8,234,375 $ 0.04-0.08 - $ Warrants exercised - $ - - $ Warrants expired/cancelled , $ - - $ Balance at December 31, 2019 31,286,847 $ 0.04-80.00 0.97 years $ - $ 0.10 Exercisable at December 31, 2019 31,286,847 $ 0.04-80.00 0.97 years $ - $ 0.10 For the year ended December 31, 2018, the Company granted 2,416,410 warrants to settle accrued payroll, 7,925,503 warrants to settle other payables, 2,725,000 warrants to settle accounts payable, 750,000 warrants issued for consulting services and 9,226,750 warrants in the issuance of shares issued for cash. For the year ended December 31, 2019, the Company granted 1,250,000 warrants in the issuance of common and preferred shares issued for cash to accredited investors, 5,650,000 warrants in the issuance of promissory notes (recorded as a debt discount valued at $151,048), 750,000 warrants for the extension of promissory notes, recorded as interest expense valued at $25,656, 500,000 warrants for settlement of accounts payable valued at $18,500 (see Note 9) and 84,375 warrants issued for consulting services valued at $3,792. Restricted Stock Units The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2017 717,500 $ 0.59 RSU’s granted - $ - RSU’s vested (310,000 ) $ - RSU’s forfeited (145,000 ) $ - Balance at December 31, 2018 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at December 31, 2019 262,500 $ 0.59 During the years ended December 31, 2019 and 2018, the Company recognized $0 and $113,189 worth of expense related to the vesting of its RSU’s, respectively. As of December 31, 2019, the Company had $155,400 worth of expense yet to be recognized for RSU’s not yet vested.

Legal Matters

Legal Matters	12 Months Ended
Legal Matters	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 9: LEGAL MATTERS The Company may, from time to time, be involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. Other than as set forth below, there are no additional material pending or threatened legal proceedings at this time. On January 28, 2019, James Katzaroff, (“ Plaintiff Release Complaint On November 25, 2019, the Company and its current and former directors entered into a Settlement Agreement with the Plaintiff. Under the terms of the Settlement Agreement, the Company has agreed to issue 500,000 shares of common stock and 500,000 warrants to the Plaintiff, make an initial payment of $33,503 by December 4, 2019 and beginning on December 16, 2019, the Company will make payments of $10,000 per month for 10 months in full satisfaction of the Separation Agreement and General Release originally entered into on July 21, 2017.

Commitment

Commitment	12 Months Ended
Commitment	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitment	NOTE 10: COMMITMENT On June 4, 2019, the Company entered into an Executive Employment Agreement (“Employment Agreement”) with Dr. Michael K. Korenko, the Company’s Chief Executive Officer. The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement. Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $180,000. Of this amount, $120,000 is booked in monthly intervals and the remaining balance is only paid upon the Company achieving a cash balance that exceeds $1,000,000. The Company has elected to record the compensation as $120,000, and upon achieving the milestone of $1,000,000 in cash balances, will record the deferred compensation at that time.

Concentrations of Credit and Ot

Concentrations of Credit and Other Risks	12 Months Ended
Concentrations of Credit and Other Risks	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Concentrations of Credit and Other Risks	NOTE 11: CONCENTRATIONS OF CREDIT AND OTHER RISKS Accounts Receivable The Company had one customer that represented 100% of the Company’s total revenues for the year ended December 31, 2019. The customer that represented 100% of the Company’s total revenue for the year ended December 31, 2019 had no net accounts receivable balance at December 31, 2019. The loss of a significant customer representing the percentage of total revenue would have a temporary adverse effect on the Company’s revenue, which would continue until the Company located new customers to replace them. The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary. As of December 31, 2019 and 2018, the Company had no allowance or bad debt expense recorded. Product Purchases Some of the products the Company might market and components thereof are currently available only from a limited number of suppliers including the source for the main component in the Company’s products, Y-90 which is only derived from one source, several of which are international suppliers. Failure to obtain deliveries from these sources could have a material adverse effect on the Company’s ability to operate.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 12: SUBSEQUENT EVENTS The Company in January 2020 paid $50,000 to redeem 100,000 shares of Series B Convertible Preferred Stock. The redemption price was agreed to by the investor. The Company issued a convertible note in the amount of $100,000 to an accredited investor. The note bears interest at 8% per annum and matures March 31, 2020. The Company granted 1,250,000 warrants with an exercise price of $0.06 per share and a term of two years with this note and amended 1,312,500 previously issued warrants held by the investor to provide for a $.06 exercise price and an expiration date of March 31, 2022. All of the notes (convertible and non-convertible) that had a maturity date of January 15, 2020 were in default, resulting in a default interest rate of 12.5% from this date through the date they were converted effective March 31, 2020. In January 2020, the Company converted 435,990 shares of Series C Convertible Preferred stock into 5,449,875 shares of common stock. On February 15, 2020, the two notes for $50,000 each were extended to August 15, 2020. In March 2020, the Company entered into agreements to issue 4,640,000 shares of common stock conditioned upon the qualification of the offer and sale of such shares under Regulation A+ for $125,280. Additionally, the Company agreed to issue 2,320,000 warrants with a term of two years and an exercise price of $.045 for a purchase price of $1,243. In March 2020, certain holders of convertible promissory notes entered into agreements to exchange certain notes totaling $526,113, including $415,000 in principal amount, $23,427 in accrued interest and an exchange premium as provided for in the note agreements of $87,686 into 19,485,668 shares of common stock effective upon the qualification of the offer and sale of such shares under Regulation A+. In connection with the holder’s agreement to enter into the exchange, the Company intends to issue 2,075,000 warrants with a two-year term and an exercise price of $0.045 per share and amend 4,400,000 previously issued warrants to provide for a $.045 exercise price and an expiration date of March 31, 2022.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Financial Statement Reclassification	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these audited financial statements so as to conform to current period classifications.
Cash Equivalents	Cash Equivalents For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.
Inventory	Inventory Inventory is reported at the lower of cost or market, determined using the first-in, first-out basis, or net realizable value. All inventories consisted of finished goods. The Company has no inventory for the years ended December 31, 2019 and 2018.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2019 and 2018, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Accounting Standards Codification (“ ASC Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures certain financial instruments including options and warrants issued during the period at fair value on a recurring basis.
Derivative Liabilities and Beneficial Conversion Feature	Derivative Liabilities and Beneficial Conversion Feature The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ ASC 815 The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation than that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings. The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using a binomial model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock. The Company accounts for the beneficial conversion feature on its convertible instruments in accordance with ASC 470-20. The Beneficial Conversion Feature (“BCF”) is normally characterized as the convertible portion or feature that provides a rate of conversion that is below market value or in the money when issued. The Company records a BCF when these criteria exist, when issued. BCFs that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. To determine the effective conversion price, the Company first allocates the proceeds received to the convertible instrument, and then use those allocated proceeds to determine the effective conversion price. The intrinsic value of the conversion option should be measured using the effective conversion price for the convertible instrument on the proceeds allocated to that instrument. The accounting for a BCF requires that the BCF be recognized by allocating the intrinsic value of the conversion option to additional paid in capital, resulting in a discount to the convertible instrument. This discount should be accreted from the date on which the BCF is first recognized through the earliest conversion date for instruments that do not have a stated redemption date.
Fixed Assets	Fixed Assets Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset. Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.
License Fees	License Fees License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. Effective March 2012, the Company entered into an exclusive license agreement with Battelle Memorial Institute regarding the use of its patented RadioGel™ technology. This license agreement originally called for a $17,500 nonrefundable license fee and a royalty based on a percent of gross sales for licensed products sold; the license agreement also contains a minimum royalty amount to be paid each year starting with 2013. The license agreement was most recently amended on December 20, 2018, and pursuant to the amendment the maintenance fee schedule was updated for minimum royalties, as well as the increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%). Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per Calendar Year 2020 $ 10,000 2021 10,000 2022 4,000 Total $ 24,000 The Company periodically reviews the carrying values of capitalized license fees and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The 2020 fee was paid in January 2020.
Patents and Intellectual Property	Patents and Intellectual Property While patents are being developed or pending, they are not being amortized. Management has determined that the economic life of the patents to be ten years and amortization, over such 10-year period and on a straight-line basis will begin once the patents have been issued and the Company begins utilization of the patents through production and sales, resulting in revenues. The Company evaluates the recoverability of intangible assets, including patents and intellectual property on a continual basis. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows. There have been no such capitalized costs in the years ended December 31, 2019 and 2018, respectively. However, a patent was filed on July 1, 2019 (No. 1811.191) filed by Michael Korenko and David Swanberg and assigned to the Company based on the Company’s proprietary particle manufacturing process. The timing of this filing was important given the Company’s plans to make IsoPet® commercially available, which it did on or about July 9, 2019. This additional patent protection will strengthen the Company’s competitive position. It is the Company’s intention to further extend this patent protection to several key countries within one year, as permitted under international patent laws and treaties.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“F ASB ASU Under ASC 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance and verify that collection of substantially all consideration is probable. The adoption of ASC 606 did not have an impact on the Company’s operations or cash flows. The Company recognized revenue as they (i) identified the contracts with ach customer; (ii) identified the performance obligation in each contract; (iii) determined the transaction price in each contract; (iv) were able to allocate the transaction price to the performance obligations in the contract; and (v) recognized revenue upon the satisfaction of the performance obligation. Upon the sales of the product to complete the procedures on the animals, the Company recognized revenue as that was considered the performance obligation. All revenue generated during the year ended December 31, 2019 related to sales of product.
Income from Grants and Deferred Income	Income from Grants and Deferred Income Government grants are recognized when all conditions of such grants are fulfilled or there is reasonable assurance that they will be fulfilled. The Company has chosen to recognize income from grants as it incurs costs associated with those grants, and until such time as it recognizes the grant as income those funds received will be classified as deferred income on the balance sheet. On December 22, 2017, the Company received notification that Washington State University awarded it $17,500 of grant funds from the sub-award project entitled “ Optimized Injectable Radiogels for High-dose Therapy of Non-Resectable Solid Tumors
Loss Per Share	Loss Per Share The Company accounts for its loss per common share by replacing primary and fully diluted earnings per share with basic and diluted earnings per share. Basic loss per share is computed by dividing loss available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents since the impact would be anti-dilutive. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued. For the given periods of loss, of the years ended December 31, 2019 and 2018, the basic earnings per share equals the diluted earnings per share. The following represent common stock equivalents that could be dilutive in the future as of December 31, 2019 and 2018, which include the following: December 31, 2019 December 31, 2018 Convertible debt 10,914,782 17,594 Preferred stock 27,372,515 44,512,740 Common stock options 34,524,580 11,318,021 Common stock warrants 31,286,847 23,052,472 Total potential dilutive securities 104,098,724 78,900,827
Research and Development Costs	Research and Development Costs Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed. The Company incurred $67,584 and $104,208 research and development costs for the years ended December 31, 2019, and 2018, respectively, all of which were recorded in the Company’s operating expenses noted on the statements of operations for the years then ended.
Advertising and Marketing Costs	Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. There were no tradeshow expenses incurred and not expensed for the years ended December 31, 2019, and 2018, respectively. During the years ended December 31, 2019 and 2018, the Company incurred $0 and $11,500, respectively, in advertising and marketing costs.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs are expensed as incurred and included in cost of materials.
Contingencies	Contingencies In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. The Company has entered into various agreements that require them to pay certain fees to consultants and/or employees that have been fully accrued for as of December 31, 2019 and 2018.
Income Taxes	Income Taxes To address accounting for uncertainty in tax positions, the Company clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition. The Company files income tax returns in the U.S. federal jurisdiction. The Company did not have any tax expense for the years ended December 31, 2019 and 2018. The Company did not have any deferred tax liability or asset on its balance sheet on December 31, 2019 and 2018. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the Company’s financial statements. For the years ended December 31, 2019 and 2018, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months. The Tax Cuts and Jobs Act (the “ Act
Stock-based Compensation	Stock-Based Compensation The Company recognizes compensation costs to employees under FASB ASC Topic 718, Compensation – Stock Compensation. Under FASB ASC Topic. 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share based compensation arrangements include stock options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation.” The update provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718. An entity shall account for the effects of a modification described in ASC paragraphs 718-20-35-3 through 35-9, unless all the following are met: (1) The fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The provisions of this update become effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The Company’s adoption of this guidance on January 1, 2018 did not have a material impact on the Company’s results of operations, financial position and related disclosures. In June 2018, the FASB issued ASU No. 2018-07 “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The guidance is effective for public companies for fiscal years, and interim fiscal periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The adoption of this standard did not have a material impact on its financial statements. The Company has determined that no amounts had to be revalued upon adoption of this amendment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates Step 2 from the goodwill impairment test. When an indication of impairment was identified after performing the first step of the goodwill impairment test, Step 2 required that an entity determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) using the same procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Under the amendments in ASU No. 2017-04, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying value. An entity would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value. In addition, an entity must consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. A public business entity that is a SEC filer should adopt the amendments in ASU No. 2017-04 for its annual, or any interim, good will impairment tests in fiscal years beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260).” The amendments in the update change the classification of certain equity-linked financial instruments (or embedded features) with down round features. The amendments also clarify existing disclosure requirements for equity-classified instruments. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (“EPS”) in accordance with Topic 260, Earnings Per Share, to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features would be subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption did not have a material impact on the Company’s financial statements. In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements,” which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not believe the guidance will have a material impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Depreciation Estimated Useful Life	Depreciation is computed using the straight-line method over the following estimated useful lives: Production equipment: 3 to 7 years Office equipment: 2 to 5 years Furniture and fixtures: 2 to 5 years
Schedule of Future Minimum Royalties	Future minimum royalties for the years ended December 31 are noted below: Calendar Year Minimum Royalties per Calendar Year 2020 $ 10,000 2021 10,000 2022 4,000 Total $ 24,000
Schedule of Dilutive Earnings Per Share	The following represent common stock equivalents that could be dilutive in the future as of December 31, 2019 and 2018, which include the following: December 31, 2019 December 31, 2018 Convertible debt 10,914,782 17,594 Preferred stock 27,372,515 44,512,740 Common stock options 34,524,580 11,318,021 Common stock warrants 31,286,847 23,052,472 Total potential dilutive securities 104,098,724 78,900,827

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
Fixed Assets (Tables)	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Production equipment $ - $ 15,182 Less accumulated depreciation - (15,182 ) $ - $ -

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
Related Party Transactions (Tables)	Dec. 31, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Transaction	As of December 31, 2019 and 2018, the Company had the following related party convertible notes outstanding: December 31, 2019 December 31, 2018 Principal Accrued Principal Accrued September 2019 $15,000 Note, 8% interest, due January 2020 $ 15,000 $ 321 $ - $ - Other related party notes - 1,054 - 1,054 March 2017 $332,195 Note, 10% interest, due May 2017 - - - - Total Convertible Notes Payable, Net $ 15,000 $ 1,375 $ - $ 1,054 Less: Debt Discount (500 ) - - - As of December 31, 2019 and December 31, 2018, the Company had the following related party notes outstanding: December 31, 2019 December 31, 2018 Principal Accrued Principal Accrued January 2019 $60,000 Note, 8% interest, due January 2020 $ 60,000 $ 4,472 $ - $ - March 2019 $48,000 Note, 8% interest, due March 2020 48,000 2,927 - - April 2019 $29,000 Note, 8% interest, due April 2020 29,000 1,559 - - July 2019 $50,000 Note 8% interest, due July 2020 50,000 1,956 - - November 2019 $50,000 Note 8% interest, due November 2020 50,000 393 - - Total Related Party Notes Payable, Net $ 237,000 $ 11,307 $ - $ -

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
Convertible Notes Payable (Tables)	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	As of December 31, 2019 and 2018, the Company had the following convertible notes outstanding: December 31, 2019 December 31, 2018 Principal Accrued Interest Principal Accrued Interest July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014 $ 45,000 $ 39,998 $ 45,000 34,603 May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015 - 17,341 - 17,341 October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $560,913, respectively - 5,953 - 5,953 January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016 - 696 - 696 May 2019 $60,000 Note convertible into common shares at $0.04 per share, 8% interest, due October 30, 2019 60,000 3,264 - - July 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,880 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,235 - - September 2019 $38,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 38,000 939 - - September 2019 $25,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 25,000 612 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,213 - - September 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 50,000 1,202 - - September 2019 $37,000 Note convertible into common shares at $0.04 per share, 8% interest, due January 15, 2020 37,000 833 - - December 2019 $50,000 Note convertible into common shares at $0.04 per share, 8% interest, due March 31, 2020 50,000 - - - Penalties on notes in default 10,618 - 8,824 - Total Convertible Notes Payable, Net $ 465,618 $ 75,166 $ 53,824 $ 58,593 Less: BCF Discount (6,187 ) - - - Less: Debt Discount (24,545 ) - - - $ 434,886 $ 75,166 $ 53,824 $ 58,593

Promissory Notes Payable (Table

Promissory Notes Payable (Tables)	12 Months Ended
Promissory Notes Payable (Tables)	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Promissory Notes Payable, Net	As of December 31, 2019 and December 31, 2018, the Company had the following promissory notes outstanding: December 31, 2019 December 31, 2018 Principal (net) Accrued Interest Principal (net) Accrued Interest February 2019, two promissory notes for $50,000 each (total of $100,000), maturing August 2019, extended to February 2020, at 8.00% interest (originally) and now 15% interest $ 100,000 $ 5,410 $ - - Debt discount (-) - - - Total Promissory Notes Payable, Net $ 100,000 $ 5,410 $ - $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Net Deferred Tax Assets	Net deferred tax assets consist of the following components as of December 31, 2019 and 2018: December 31, 2019 December 31, 2018 Deferred tax assets: Net operating loss carryover $ 5,890,000 $ 5,760,000 Interest expense 15,000 - Related party accrual 23,400 2,300 Capital Loss Carryover 3,400 3,400 Deferred tax liabilities Depreciation (2,100 ) (2,100 ) Valuation allowance (5,929,700 ) (5,763,600 ) Net deferred tax asset $ - $ -
Schedule of Federal Income Tax Rate	The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2019 and 2018 due to the following: December 31, 2019 December 31, 2018 Book income (loss) $ (338,100 ) $ (1,617,600 ) Forgiveness of debt (7,200 ) - Depreciation (1,100 ) (1,100 ) Interest expense 15,000 - Related party accrual 21,100 (108,300 ) Meals and entertainment - 300 Stock for services 2,600 100 Options expense 134,000 302,000 Non-cash interest expense 39,900 1,046,900 Other non-deductible expenses - 261,800 Valuation allowance 133,800 115,900 Income tax expense $ - $ -

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
Stockholders' Deficit (Tables)	Dec. 31, 2019
Equity [Abstract]
Schedule of Changes in Stock Option	The following schedule summarizes the changes in the Company’s stock options: Weighted Weighted Options Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2017 152,813 $ 4.00-120.00 3.91 years $ - $ 1.08 Options granted 11,165,208 $ 0.11 - $ - Options exercised - $ - - $ - Options expired - $ - - $ - Balance at December 31, 2018 11,318,021 $ 0.11-120.00 - $ - $ 0.24 Options granted 23,252,809 $ 0.025 4-0.04 - $ - Options exercised - $ - - $ - Options expired (46,250 ) $ - - $ - Balance at December 31, 2019 34,524,580 $ 0.024-120.00 6.49 years $ 277,973 $ 0.08 Exercisable at December 31, 2019 34,428,955 $ 0.024-120.00 6.48 years $ 276,729 $ 0.08
Schedule of Changes in Stock Warrants	The following schedule summarizes the changes in the Company’s common stock warrants: Weighted Weighted Warrants Outstanding Average Average Number Exercise Remaining Aggregate Exercise Of Price Contractual Intrinsic Price Shares Per Share Life Value Per Share Balance at December 31, 2017 38,026 $ 0.14 1.19 years $ 749 $ 0.32 Warrants granted 23,043,663 $ - - $ Warrants exercised - $ - - $ Warrants expired/cancelled (29,217 ) $ - - $ Balance at December 31, 2018 23,052,472 $ 0.08-80.00 1.77 years $ - $ 0.08 Warrants granted 8,234,375 $ 0.04-0.08 - $ Warrants exercised - $ - - $ Warrants expired/cancelled , $ - - $ Balance at December 31, 2019 31,286,847 $ 0.04-80.00 0.97 years $ - $ 0.10 Exercisable at December 31, 2019 31,286,847 $ 0.04-80.00 0.97 years $ - $ 0.10
Schedule of Changes in Restricted Stock Units	The following schedule summarizes the changes in the Company’s restricted stock units: Weighted Number Average Of Grant Date Shares Fair Value Balance at December 31, 2017 717,500 $ 0.59 RSU’s granted - $ - RSU’s vested (310,000 ) $ - RSU’s forfeited (145,000 ) $ - Balance at December 31, 2018 262,500 $ 0.59 RSU’s granted - $ - RSU’s vested - $ - RSU’s forfeited - $ - Balance at December 31, 2019 262,500 $ 0.59

Organization & Basis of Prese_2

Organization & Basis of Presentation (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Mar. 31, 2020	Nov. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Common stock, authorized			950,000,000	950,000,000
Common stock, par value			$ 0.001	$ 0.001
Preferred stock, authorized			20,000,000	20,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Current operation activities			$ 2,300,000
Proceeds from raising capital			$ 3,000,000
Capital raising description			The intent is to obtain up to $3,000,000 in tranches of $250,000 over time.
Proceeds from issuance of common stock			$ 50,000	$ 683,140
Outstanding debt amount			300,000
Accrued interest			75,166	58,593
Debt conversion, amount converted				$ 7,290,473
Cash			20,381
Offering shares of common stock		150,000,000
Subsequent Event [Member]
Proceeds from issuance of common stock	$ 125,280
Outstanding debt amount	415,000
Accrued interest	23,427
Debt conversion, amount converted	$ 87,686
Minimum [Member]
Current operation activities			5,000,000
Maximum [Member]
Current operation activities			$ 10,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Dec. 22, 2017	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Inventory
Production equipment capitalized cost		2,500
Fixed assets capitalized cost		1,500
Nonrefundable license fee		$ 17,500
Royalties percentage, description		The increase in royalties from one percent (1%) to two percent (2%), then on October 8, 2019 to reduce the fee back to one percent (1%).
Economic life of the patent		10 years
Income from grants	$ 17,500		17,500
Research and development costs		$ 67,584	104,208
Advertising and marketing costs		0	11,500
Income tax description	The Act reduces the US federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings.
Income tax federal corporate tax rate	21.00%
Reduction of net deferred tax assets	$ 3,300,000	$ 133,800	$ 115,900

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Depreciation Estimated Useful Life (Details)	12 Months Ended
	Dec. 31, 2019
Production Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	3 years
Production Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	7 years
Office Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Office Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	2 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of asset	5 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Future Minimum Royalties (Details)	Dec. 31, 2019USD ($)
Accounting Policies [Abstract]
2020	$ 10,000
2021	10,000
2022	4,000
Total	$ 24,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Dilutive Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	104,098,724	78,900,827
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	10,914,782	17,594
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	27,372,515	44,512,740
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	34,524,580	11,318,021
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential dilutive securities	31,286,847	23,052,472

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
Fixed Assets (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Depreciation expense
Piece of Equipment [Member]
Property, Plant and Equipment [Line Items]
Proceeds from sale of equipment	$ 0
Equipment value		$ 0

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - Production Equipment [Member] - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Production equipment		$ 15,182
Less accumulated depreciation		(15,182)
Net fixed assets

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Sep. 24, 2019

Apr. 29, 2019

Mar. 27, 2019

Feb. 20, 2019

Jan. 24, 2019

Oct. 10, 2018

Aug. 09, 2018

Apr. 30, 2020

Mar. 31, 2020

Mar. 31, 2017

Dec. 31, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Nov. 25, 2020

Dec. 31, 2019

Dec. 31, 2018

Nov. 25, 2019

Aug. 20, 2019

Jul. 05, 2019

Oct. 31, 2018

Oct. 19, 2018

Related Party Transaction [Line Items]

Accrued interest payable

$ 75,166

$ 58,593

$ 75,166

$ 58,593

Debt instrument interest rate

8.00%

Note maturity date

Aug. 20,
2019

Debt conversion, amount converted

7,290,473

Advances from related party

237,000

Proceeds from warrants

750,000

Debt discount

24,545

Notes payable to related party

237,000

Related party payables

32,110

38,610

32,110

38,610

Gain loss on conversion of debt

(18,744)

605,601

Conversion shares issued

Convertible note payable

465,618

$ 53,824

465,618

53,824

Forecast [Member]

Related Party Transaction [Line Items]

Accrued interest payable

$ 619

Debt conversion, amount converted

$ 3,124

Debt conversion, shares issued

694,178

Convertible note payable

$ 15,000

Accounts Payable and Notes Payable [Member]

Related Party Transaction [Line Items]

Gain loss on conversion of debt

$ 35,400

Number of stock issued for settlement of debt

450,000

Number of stock issued for settlement of debt, value

$ 50,400

Number of warrant granted

225,000

Subsequent Event [Member]

Related Party Transaction [Line Items]

Accrued interest payable

$ 23,427

Debt conversion, amount converted

87,686

Director [Member]

Related Party Transaction [Line Items]

Accrued interest payable

11,307

Debt instrument interest rate

8.00%

Note maturity date

Jul. 5,
2020

Mar. 27,
2020

Jan. 24,
2020

Nov. 25,
2020

Interest expenses, related party

11,307

Notes payable to related party

$ 29,000

$ 48,000

$ 60,000

$ 50,000

Debt term

1 year

CEO [Member] | Subsequent Event [Member]

Related Party Transaction [Line Items]

Related party payables

$ 15,000

Chairman [Member] | April 2020 [Member]

Related Party Transaction [Line Items]

Conversion shares issued

385,302

Series B Convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Conversion price per share

$ 0.08

Common Stock [Member]

Related Party Transaction [Line Items]

Number of common stock issued for compensation

4,832,820

Warrant to purchase of common stock

2,416,410

Accrued compensation

$ 541,276

Number of warrants issued, value

238,973

Gain loss on conversion of debt

586,936

Common Stock [Member]

Related Party Transaction [Line Items]

Conversion shares issued

5,375

$ 6,462

$ 6,553

$ 273

$ 51

$ 490

$ 718

Path Forward and Restructuring Agreement [Member]

Related Party Transaction [Line Items]

Conversion price per share

$ 0.032

Debt conversion, amount converted

$ 500,000

Path Forward and Restructuring Agreement [Member] | Series B Convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Debt conversion, shares issued

385,302

Path Forward and Restructuring Agreement [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Debt conversion, shares issued

6,250,000

Path Forward and Restructuring Agreement [Member] | Warrant [Member]

Related Party Transaction [Line Items]

Debt conversion, shares issued

5,533,138

Warrant exercise price per share

$ 0.08

Old Related Party Note [Member]

Related Party Transaction [Line Items]

Accrued interest payable

$ 1,054

1,054

Convertible Notes Payable [Member]

Related Party Transaction [Line Items]

Interest expenses, related party

$ 321

$ 29,650

Director and Major Stockholder [Member] | Related Party Note [Member]

Related Party Transaction [Line Items]

Accrued interest payable

$ 51,576

Debt instrument interest rate

10.00%

Note maturity date

May 9,
2018

Note maturity date, description

The note holder agreed to an extension of the due date until May 9, 2018.

Conversion price per share

$ 0.104

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Debt instrument interest rate

8.00%

12.50%

Note maturity date

Jan. 15,
2020

Advances from related party

$ 20,000

Repayment of advance from related party

$ 5,000

Advances from related party, outstanding balance

$ 15,000

Proceeds from warrants

150,000

Debt discount

$ 3,721

Debt instrument description

The Company recognized a discount on the convertible note of $3,721 as a result of the warrants which are being amortized over the life of the note through January 15, 2020.

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transaction (Details) - USD ($)	Dec. 31, 2019	Nov. 30, 2019	Sep. 30, 2019	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Feb. 20, 2019	Jan. 31, 2019	Dec. 31, 2018	Mar. 31, 2017
Related Party Transaction [Line Items]
Principal							$ 100,000
Total Notes Payable, Net	$ 237,000
Accrued interest	75,166								58,593
Less: Debt Discount	(24,545)
Convertible notes payable, related party, net	14,500
Convertible Note Payable [Member]
Related Party Transaction [Line Items]
Principal	15,000
Accrued interest	1,375								1,054
Less: Debt Discount	(500)
Convertible notes payable, related party, net	14,500
Convertible Note Payable [Member] \| Related Party One [Member]
Related Party Transaction [Line Items]
Principal	15,000		$ 15,000
Accrued interest	321
Convertible Note Payable [Member] \| Other Related Party Notes [Member]
Related Party Transaction [Line Items]
Principal
Accrued interest	1,054								1,054
Convertible Note Payable [Member] \| Related Party Two [Member]
Related Party Transaction [Line Items]
Principal										$ 332,195
Accrued interest
Related Party Notes Payable [Member]
Related Party Transaction [Line Items]
Total Notes Payable, Net	237,000
Accrued interest	11,307
Related Party Notes Payable [Member] \| Related Party Three [Member]
Related Party Transaction [Line Items]
Principal								$ 60,000
Total Notes Payable, Net	60,000
Accrued interest	4,472
Related Party Notes Payable [Member] \| Related Party Four [Member]
Related Party Transaction [Line Items]
Principal						$ 48,000
Total Notes Payable, Net	48,000
Accrued interest	2,927
Related Party Notes Payable [Member] \| Related Party Five [Member]
Related Party Transaction [Line Items]
Principal					$ 29,000
Total Notes Payable, Net	29,000
Accrued interest	1,559
Related Party Notes Payable [Member] \| Related Party Six [Member]
Related Party Transaction [Line Items]
Principal				$ 50,000
Total Notes Payable, Net	50,000
Accrued interest	1,956
Related Party Notes Payable [Member] \| Related Party Seven [Member]
Related Party Transaction [Line Items]
Principal		$ 50,000
Total Notes Payable, Net	50,000
Accrued interest	$ 393

Related Party Transactions - _2

Related Party Transactions - Schedule of Related Party Transaction (Details) (Parenthetical) - USD ($)	1 Months Ended
	Nov. 30, 2019	Sep. 30, 2019	Jul. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Mar. 31, 2017	Dec. 31, 2019	Feb. 20, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Note, amount									$ 100,000
Note, interest rate									8.00%
Convertible Note Payable [Member]
Related Party Transaction [Line Items]
Note, amount								$ 15,000
Convertible Note Payable [Member] \| Related Party One [Member]
Related Party Transaction [Line Items]
Note, amount		$ 15,000						15,000
Note, interest rate		8.00%
Note due date, description		January 2020
Convertible Note Payable [Member] \| Related Party Two [Member]
Related Party Transaction [Line Items]
Note, amount							$ 332,195
Note, interest rate							10.00%
Note due date, description							May 2017
Related Party Notes Payable [Member] \| Related Party Three [Member]
Related Party Transaction [Line Items]
Note, amount						$ 60,000
Note, interest rate						8.00%
Note due date, description						January 2020
Related Party Notes Payable [Member] \| Related Party Four [Member]
Related Party Transaction [Line Items]
Note, amount					$ 48,000
Note, interest rate					8.00%
Note due date, description					March 2020
Related Party Notes Payable [Member] \| Related Party Five [Member]
Related Party Transaction [Line Items]
Note, amount				$ 29,000
Note, interest rate				8.00%
Note due date, description				April 2020
Related Party Notes Payable [Member] \| Related Party Six [Member]
Related Party Transaction [Line Items]
Note, amount			$ 50,000
Note, interest rate			8.00%
Note due date, description			July 2020
Related Party Notes Payable [Member] \| Related Party Seven [Member]
Related Party Transaction [Line Items]
Note, amount	$ 50,000
Note, interest rate	8.00%
Note due date, description	November 2020

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)

Sep. 30, 2019

Aug. 20, 2019

Jul. 31, 2019

May 31, 2019

Feb. 20, 2019

Oct. 30, 2018

Oct. 10, 2018

Jan. 31, 2018

Mar. 31, 2020

Oct. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Jul. 31, 2018

Apr. 19, 2018

Debt Instrument [Line Items]

Convertible notes payable

$ 465,618

$ 53,824

Debt discount

24,545

Debt conversion of convertible debt

7,290,473

Debt instrument interest rate

8.00%

Debt principal amount

$ 100,000

Gain loss on conversion of debt

(18,744)

605,601

Debt maturity date

Aug. 20,
2019

Proceeds from convertible debt

500,000

50,000

Amortization of BCF discount

55,740

Subsequent Event [Member]

Debt Instrument [Line Items]

Debt conversion of convertible debt

$ 87,686

Two Noteholders [Member]

Debt Instrument [Line Items]

Debt maturity date

Aug. 20,
2020

Series B Convertible Preferred Stock [Member]

Debt Instrument [Line Items]

Principal amount, percentage

100.00%

Conversion price per share

$ 0.08

Path Forward Agreement [Member]

Debt Instrument [Line Items]

Debt instrument, description

These shares were subject to a restriction on any sales below $0.16 through December 31, 2018 and will have volume limitations on any sales below $0.08 during the first six months of 2019.

Path Forward Agreement [Member] | Series B Convertible Preferred Stock [Member]

Debt Instrument [Line Items]

Conversion of debt into stock

2,610,453

Conversion price per share

$ 0.032

Convertible Note Payable [Member]

Debt Instrument [Line Items]

Interest expenses

16,563

187,741

Debt discount

500

Debt principal amount

15,000

May 2017 Notes [Member]

Debt Instrument [Line Items]

Convertible notes payable

3,136,506

Debt discount

$ 2,419,240

Note due date, description

December 2017 due date which was extended to May 2018.

November 2017 Note [Member]

Debt Instrument [Line Items]

Convertible notes payable

$ 166,666

Debt discount

92,004

Principal amount, percentage

130.00%

Repurchase of notes

$ 228,332

Convertible Secured Debentures and Convertible Promissory Note [Member] | Path Forward Agreement [Member]

Debt Instrument [Line Items]

Debt conversion of convertible debt

$ 2,253,538

Conversion of debt into stock

37,792,407

Convertible Notes [Member]

Debt Instrument [Line Items]

Convertible notes payable

$ 50,000

Conversion of debt into stock

1,500,000

Conversion price per share

$ 0.112

Debt instrument interest rate

8.00%

Capital raise

$ 500,000

Debt principal amount

$ 60,000

Interest and other costs

10,000

Gain loss on conversion of debt

$ 108,916

Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Convertible notes payable

$ 300,000

$ 50,000

Debt discount

$ 10,000

Conversion price per share

$ 0.04

$ 0.032

$ 0.04

Debt instrument interest rate

8.00%

Debt maturity date

Jan. 15,
2020

Mar. 31,
2020

Proceeds from convertible debt

$ 250,000

Shares issued price per share

$ 1.20

Number of warrants issued

625,000

Warrants exercise price

$ 0.06

Warrants term

2 years

Fair value of warrants

$ 14,299

Convertible Promissory Note [Member] | Subsequent Event [Member]

Debt Instrument [Line Items]

Debt instrument interest rate

12.50%

Convertible Promissory Note [Member] | Qualified Financing [Member]

Debt Instrument [Line Items]

Debt maturity date

Oct. 30,
2019

Proceeds from convertible debt

$ 250,000

Convertible Promissory Note [Member] | Qualified Financing [Member] | Note Holders [Member]

Debt Instrument [Line Items]

Shares issued price per share

$ 1.20

Number of warrants issued

625,000

Warrants exercise price

$ 0.04

Warrants term

2 years

Fair value of warrants

$ 12,592

Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member]

Debt Instrument [Line Items]

Proceeds from convertible debt

$ 250,000

Shares issued price per share

$ 1.20

Number of warrants issued

3,000,000

Warrants term

2 years

Fair value of warrants

$ 91,716

Debt instrument beneficial conversion feature

$ 59,957

Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member] | Minimum [Member]

Debt Instrument [Line Items]

Warrants exercise price

$ 0.06

Convertible Promissory Note [Member] | Qualified Financing [Member] | Two Noteholders [Member] | Maximum [Member]

Debt Instrument [Line Items]

Warrants exercise price

$ 0.08

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Principal	$ 465,618	$ 53,824
Accrued interest	75,166	58,593
Penalties on notes in default principal (net)	10,618	8,824
Penalties on notes in default accrued interest
Less: BCF Discount	(6,187)
Less: Debt Discount	(24,545)
Convertible notes payable, principal (net)	434,886	53,824
Convertible notes payable, accrued interest	75,166	58,593
Convertible Notes Payable One [Member]
Debt Instrument [Line Items]
Principal	45,000	45,000
Accrued interest	39,998	34,603
Convertible Notes Payable Two [Member]
Debt Instrument [Line Items]
Principal
Accrued interest	17,341	17,341
Convertible Notes Payable Three [Member]
Debt Instrument [Line Items]
Principal
Accrued interest	5,953	5,953
Convertible Notes Payable Four [Member]
Debt Instrument [Line Items]
Principal
Accrued interest	696	696
Convertible Notes Payable Five [Member]
Debt Instrument [Line Items]
Principal	60,000
Accrued interest	3,264
Convertible Notes Payable Six [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	1,880
Convertible Notes Payable Seven [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	1,235
Convertible Notes Payable Eight [Member]
Debt Instrument [Line Items]
Principal	38,000
Accrued interest	939
Convertible Notes Payable Nine [Member]
Debt Instrument [Line Items]
Principal	25,000
Accrued interest	612
Convertible Notes Payable Ten [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	1,213
Convertible Notes Payable Eleven [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest	1,202
Convertible Notes Payable Twelve [Member]
Debt Instrument [Line Items]
Principal	37,000
Accrued interest	833
Convertible Notes Payable Thirteen [Member]
Debt Instrument [Line Items]
Principal	50,000
Accrued interest

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

Aug. 31, 2012

Jul. 31, 2012

Dec. 31, 2019

Sep. 30, 2019

Jul. 31, 2019

May 31, 2019

Mar. 31, 2016

Dec. 31, 2015

Oct. 31, 2015

Feb. 20, 2019

Dec. 31, 2018

Jan. 31, 2016

May 31, 2015

Debt Instrument [Line Items]

Debt principal amount

$ 100,000

Convertible Notes Payable One [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 1,060,000

Debt conversion price per share

$ 4.60

Debt interest rate

12.00%

Debt maturity date description

January 2014

December 2013

Convertible Notes Payable Two [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 605,000

Debt conversion price per share

$ 1

Debt maturity date description

September 30, 2015

Convertible Notes Payable Two [Member] | Minimum [Member]

Debt Instrument [Line Items]

Debt interest rate

8.00%

Convertible Notes Payable Two [Member] | Maximum [Member]

Debt Instrument [Line Items]

Debt interest rate

10.00%

Convertible Notes Payable Three [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 613,000

Debt conversion price per share

$ 1

Debt interest rate

8.00%

Debt maturity date description

June 30, 2016

Debt discount

$ 0

$ 560,913

Convertible Notes Payable Four [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 345,000

Debt conversion price per share

$ 1

Debt interest rate

8.00%

Debt maturity date description

June 30, 2016

Convertible Notes Payable Five [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 60,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

October 30, 2019

Convertible Notes Payable Six [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Seven [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Eight [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 38,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Nine [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 25,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Ten [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Eleven [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Twelve [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 37,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

January 15, 2020

Convertible Notes Payable Thirteen [Member]

Debt Instrument [Line Items]

Debt principal amount

$ 50,000

Debt conversion price per share

$ 0.04

Debt interest rate

8.00%

Debt maturity date description

March 31, 2020

Promissory Notes Payable (Detai

Promissory Notes Payable (Details Narrative) - USD ($)	Aug. 20, 2019	Feb. 20, 2019	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Debt principal amount		$ 100,000
Debt maturity date		Aug. 20, 2019
Debt instrument interest rate		8.00%
Amortized debt discount			$ 134,034	$ 791,928
Number of warrants received	750,000
Accrued interest paid	$ 4,000
Interest expense			261,374	5,649,546
Accrued interest payable			$ 75,166	$ 58,593
Two Noteholders [Member]
Debt Instrument [Line Items]
Debt maturity date	Aug. 20, 2020
Two Noteholders [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate increase	8.00%
Two Noteholders [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate increase	15.00%
Noteholders One [Member]
Debt Instrument [Line Items]
Number of warrants received	375,000
Noteholders Two [Member]
Debt Instrument [Line Items]
Number of warrants received	375,000
Promissory Notes One [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 50,000
Promissory Notes Two [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 50,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Warrant to purchase of shares			1,250,000
Fair value of warrants debt discount			$ 28,721
Amortized debt discount			28,721
Interest expense			9,410
Accrued interest payable			$ 5,410

Promissory Notes Payable - Sche

Promissory Notes Payable - Schedule of Promissory Notes Payable, Net (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Principal (net)	$ 100,000
Accrued Interest	75,166	58,593
Debt discount	24,545
Promissory Notes Payable One [Member]
Principal (net)	100,000
Accrued Interest	5,410
Debt discount
Promissory Notes Payable [Member]
Principal (net)	100,000
Accrued Interest	5,410
Debt discount

Promissory Notes Payable - Sc_2

Promissory Notes Payable - Schedule of Promissory Notes Payable, Net (Details) (Parenthetical) - USD ($)	1 Months Ended
	Feb. 28, 2019	Feb. 20, 2019
Note, amount		$ 100,000
Note, interest rate		8.00%
Promissory Notes Payable One [Member]
Note, amount	$ 50,000
Promissory Notes Payable Two [Member]
Note, amount	50,000
Promissory Notes Payable [Member]
Note, amount	$ 100,000
Note due date, description	August 2019
Note, interest rate	8.00%
Debt instrument, interest rate increase	15.00%
Promissory Notes Payable [Member] \| Extended Maturity [Member]
Note due date, description	extended to February 2020

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 22, 2017	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income tax description	The Act reduces the US federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings.
US federal corporate tax rate	21.00%
Reduction of net deferred tax assets	$ 3,300,000	$ 133,800	$ 115,900
Net operating loss carryforwards		$ 28,045,000

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net operating loss carryover	$ 5,890,000	$ 5,760,000
Interest expense	15,000
Related party accrual	23,400	2,300
Capital Loss Carryover	3,400	3,400
Deferred tax liabilities Depreciation	(2,100)	(2,100)
Valuation allowance	(5,929,700)	(5,763,600)
Net deferred tax asset

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax Rate (Details) - USD ($)	Dec. 22, 2017	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Book income (loss)		$ (338,100)	$ (1,617,600)
Forgiveness of debt		(7,200)
Depreciation		(1,100)	(1,100)
Interest expense		15,000
Related party accrual		21,100	(108,300)
Meals and entertainment			300
Stock for services		2,600	100
Options expense		134,000	302,000
Non-cash interest expense		39,900	1,046,900
Other non-deductible expenses			261,800
Valuation allowance	$ 3,300,000	133,800	115,900
Income tax expense

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Mar. 28, 2019	Jun. 21, 2016	Dec. 31, 2019	Nov. 30, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 31, 2019	Oct. 31, 2018	Jun. 30, 2015	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 27, 2019	Oct. 08, 2018	Mar. 31, 2016
Class of Stock [Line Items]
Common stock shares authorized			950,000,000								950,000,000				950,000,000				950,000,000	950,000,000
Common stock par value			$ 0.001								$ 0.001				$ 0.001				$ 0.001	$ 0.001
Common stock shares issued			184,845,821								184,845,821				163,445,736				184,845,821	163,445,736
Common stock shares outstanding			184,845,821								184,845,821				163,445,736				184,845,821	163,445,736
Preferred stock shares authorized			20,000,000								20,000,000				20,000,000				20,000,000	20,000,000
Preferred stock par value			$ 0.001								$ 0.001				$ 0.001				$ 0.001	$ 0.001
Gross proceeds from preferred stock																			$ 50,000	$ 55,000
Number of shares issued				150,000,000
Stock issued for accounts payable and accrued expenses								$ 1,062,500			$ 21,400	$ 22,500			$ 1,665,296
Stock issued for accounts payable and accrued expenses, shares								43,900
Number of shares issued for litigation settlement								500,000
Number of stock issued for services								312,500												1,250
Number of stock issued for services, value								$ 12,500				$ 12,500						$ 449		$ 449
Number of shares issued in conversion of vested restricted stock units								385,000
Gain loss on conversion of debt																			$ (18,744)	$ 605,601
Stock issued during period for conversion of shares, value
Number of shares issued, value														$ 100,000	738,140
Number of stock options expired																			46,250
Recognized a gain on this transaction																			$ 34,106
Stock based compensation																			608,588	$ 1,164,885
Debt discount			$ 24,545								$ 24,545								24,545
Interest expense																			$ 261,374	5,649,546
Settlement Agreement [Member]
Class of Stock [Line Items]
Number of stock options issued					1,000,000
Option vesting period					10 years
Options issued for settlement of accounts payable					$ 33,829
Settlement of Debt [Member]
Class of Stock [Line Items]
Settlement and conversion of debt, value																				3,545,378
Convertible debt accrued interest																				506,245
Derivative liabilities															$ 4,823,363					4,823,363
Gain loss on conversion of debt																				1,694,005
Promissory Notes [Member]
Class of Stock [Line Items]
Warrant to purchase of common stock			1,250,000								1,250,000								1,250,000
Interest expense																			$ 9,410
Stock Option [Member]
Class of Stock [Line Items]
Stock based compensation																			$ 608,588	$ 1,164,885
Restricted Stock Units [Member]
Class of Stock [Line Items]
Number of warrants granted
Restricted stock expense																			$ 0	$ 113,189
Stock options expense yet to be recognized			$ 155,400								$ 155,400								$ 155,400
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued								18,390,225
Warrant [Member]
Class of Stock [Line Items]
Number of stock issued for services																			84,375
Number of stock issued for services, value																			$ 3,792
Warrants issued for extension of notes payable																			750,000
Interest expense																			25,656
Shres issued for settlement of accounts payable																			$ 18,500
Shres issued for settlement of accounts payable, shares																			500,000
Warrant [Member] \| Accrued Payroll [Member]
Class of Stock [Line Items]
Number of warrants granted																				2,416,410
Warrant [Member] \| Other Payable [Member]
Class of Stock [Line Items]
Number of warrants granted																				7,925,503
Warrant [Member] \| Accounts Payable [Member]
Class of Stock [Line Items]
Number of warrants granted																				2,725,000
Warrant [Member] \| Consulting Service [Member]
Class of Stock [Line Items]
Number of warrants granted																				750,000
Warrant [Member] \| Shares Issued for Cash [Member]
Class of Stock [Line Items]
Number of warrants granted																				9,226,750
Warrant [Member] \| Promissory Notes [Member]
Class of Stock [Line Items]
Number of warrants granted																			5,650,000
Debt discount			$ 151,048								$ 151,048								$ 151,048
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized			5,000,000						5,000,000		5,000,000				5,000,000				5,000,000	5,000,000		5,000,000
Preferred stock par value																						$ 0.001
Preferred stock, liquidation preference per share									$ 1
Conversion price per share									$ 0.08
Voting percentage									Subject to certain conditions set forth in the Series B Certificate of Designation, in the event of a Change of Control (defined in the Series B Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series B Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series B Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage									100.00%
Number of shares issued upon conversion								1,471,218
Preferred shares exchange								821,292
Settlement and conversion of debt																				2,995,755
Preferred stock issued for cash																				110,000
Preferred stock issued for cash, value																				$ 55,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized			5,000,000				5,000,000				5,000,000			5,000,000	5,000,000				5,000,000	5,000,000	5,000,000
Preferred stock par value																					$ 0.001
Preferred stock, liquidation preference per share							$ 1							$ 1
Conversion price per share							$ 0.08							$ 0.08
Voting percentage							Subject to certain conditions set forth in the Series C Certificate of Designation, in the event of a Change of Control (defined in the Series C Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series C Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series B Convertible Preferred in cash at a price per share of Series C Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage							100.00%
Number of shares issued								821,292
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized			5,000,000							2,500,000	5,000,000				5,000,000				5,000,000	5,000,000			2,500,000
Preferred stock, liquidation preference per share										$ 5
Conversion price per share										$ 4
Gross proceeds from preferred stock										$ 5,000,000
Voting percentage										Subject to certain conditions set forth in the Series A Certificate of Designation, in the event of a Change of Control (defined in the Series A Certificate of Designation as the time at which as a third party not affiliated with the Company or any holders of the Series A Convertible Preferred shall have acquired, in one or a series of related transactions, equity securities of the Company representing more than fifty percent 50% of the outstanding voting securities of the Company), the Company, at its option, will have the right to redeem all or a portion of the outstanding Series A Convertible Preferred in cash at a price per share of Series A Convertible Preferred equal to 100% of the Liquidation Preference.
Redemption percentage										100.00%
Stock issued during period for conversion of shares, shares																				1,532,476
Stock issued during period for conversion of shares, value																				$ 4,678,380
Conversion of debt, shares																				1,225,981
Series A Convertible Preferred Stock [Member] \| Maximum [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																							5,000,000
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued																				17,078,500
Warrant to purchase of common stock															2,416,410					2,416,410
Settlement and conversion of debt																				128,528,788
Gain loss on conversion of debt																				$ 586,936
Number of shares issued, value																				683,140
Board of Directors [Member]
Class of Stock [Line Items]
Common stock shares authorized	950,000,000																				2,000,000,000
Reverse stock split	reverse 1-for-8 stock split
Accredited Investors [Member]
Class of Stock [Line Items]
Proceeds from equity financing								$ 100,000
Accredited Investors [Member] \| Warrant [Member]
Class of Stock [Line Items]
Warrant to purchase of common stock								1,250,000
Accredited Investors [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued								1,250,000
Accredited Investors [Member] \| Warrant [Member]
Class of Stock [Line Items]
Number of warrants granted																			1,250,000
Accredited Investors [Member] \| Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares issued								100,000
Officers and Consultants [Member]
Class of Stock [Line Items]
Gain loss on conversion of debt																				1,256,972
Number of common stock for accrued compensation, value																				1,665,285
Officers and Consultants [Member] \| Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of common stock for accrued compensation																				200,000
Officers and Consultants [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Number of common stock for accrued compensation																				$ 7,782,820
Consultants [Member]
Class of Stock [Line Items]
Number of stock options issued					50,000	382,500
Stock options vesting period description						Vest through June 30, 2020
Number of stock options expired		46,250
Number of stock options expired, value																			$ 6,529
Option vesting period					10 years
Options issued for settlement of accounts payable					$ 16,915
Consultants [Member] \| Accounts Payable [Member]
Class of Stock [Line Items]
Number of stock options issued			370,309
Option vesting period			10 years
Options issued for settlement of accounts payable			$ 14,812
Consultants [Member] \| Through June 30, 2020 [Member]
Class of Stock [Line Items]
Number of stock options expired, value																			$ 2,176
Dr. Korenko [Member] \| 2015 Omnibus Securities and Incentive Plan [Member]
Class of Stock [Line Items]
Number of stock options issued																			21,000,000
Stock options vesting period description																			The vesting of the options are as follows: (i) 50% vested in equal amounts at the end of each of the two successive calendar quarters (25% for each of the quarters September 30, 2019 and December 31, 2019); (ii) 25% upon the Company filing a patent; and (iii) 25% upon the first commercial sale of IsoPet®.
Fair value of options																			$ 585,144

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Changes in Stock Option (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Options Outstanding Beginning Balance	11,318,021	152,813
Number of Options granted	23,252,809	11,165,208
Number of Options exercised
Number of Options expired	(46,250)
Number of Shares Options Outstanding Ending Balance	34,524,580	11,318,021
Number of Shares Options Exercisable	34,428,955
Exercise Price Per Share granted		$ 0.11
Exercise Price Per Share exercised
Exercise Price Per Share expired
Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning	0 years	3 years 10 months 28 days
Weighted Average Remaining Contractual Life (in years) Outstanding, Ending	6 years 5 months 27 days	0 years
Weighted Average Remaining Contractual Life (in years) Exercisable	6 years 5 months 23 days	0 years
Aggregate Intrinsic Value Outstanding Beginning
Aggregate Intrinsic Value Outstanding Ending	277,973
Aggregate Intrinsic Value Exercisable	$ 277,973
Weighted Average Exercise Price Per Share Outstanding Beginning	$ 0.24	$ 1.08
Weighted Average Exercise Price Per Share Options granted
Weighted Average Exercise Price Per Share Options exercised
Weighted Average Exercise Price Per Share Options expired
Weighted Average Exercise Price Per Share Outstanding Ending	0.08	0.24
Weighted Average Exercise Price Per Share Exercisable	0.08
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	0.11	4
Exercise Price Per Share granted	0.0254
Exercise Price Per Share exercised
Exercise Price Per Share expired
Exercise Price Per Share Outstanding Ending Balance	0.024	0.11
Exercise Price Per Share Exercisable	0.024
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Outstanding Beginning Balance	120	120
Exercise Price Per Share granted	0.04
Exercise Price Per Share exercised
Exercise Price Per Share expired
Exercise Price Per Share Outstanding Ending Balance	120	$ 120
Exercise Price Per Share Exercisable	$ 120

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Changes in Stock Warrants (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Warrants Outstanding Beginning	23,052,472	38,026
Number of Shares, Warrants granted	8,234,375	23,043,663
Number of Shares, Warrants exercised
Number of Shares, Warrants expired/cancelled		(29,217)
Number of Shares, Warrants Outstanding Ending	31,286,847	23,052,472
Number of Shares, Warrants Exercisable Ending	31,286,847
Exercise Price Per Share Warrants Outstanding Beginning		$ 0.14
Exercise Price Per Share Warrants granted
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	1 year 9 months 7 days	1 year 2 months 8 days
Weighted Average Remaining Contractual Life Warrants Outstanding Ending	11 months 19 days	1 year 9 months 7 days
Weighted Average Remaining Contractual Life Warrants Exercisable	11 months 19 days
Aggregate Intrinsic Value Outstanding Beginning		$ 749
Aggregate Intrinsic Value Outstanding Ending
Aggregate Intrinsic Value Exercisable
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning	$ 0.08	$ 0.32
Weighted Average Exercise Price Per Share Exercise Price Warrants granted
Weighted Average Exercise Price Per Share Exercise Price Warrants exercised
Weighted Average Exercise Price Per Share Exercise Price Warrants expired/cancelled
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending	0.10	0.08
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable	0.10
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	0.08
Exercise Price Per Share Warrants granted	0.04
Exercise Price Per Share Warrants Outstanding Ending	0.04	0.08
Exercise Price Per Share Exercisable	0.04
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share Warrants Outstanding Beginning	80
Exercise Price Per Share Warrants granted	0.08
Exercise Price Per Share Warrants Outstanding Ending	80	$ 80
Exercise Price Per Share Exercisable	$ 80

Stockholders' Deficit - Sched_3

Stockholders' Deficit - Schedule of Changes in Restricted Stock Units (Details) - Restricted Stock Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, RSU's Outstanding Beginning	262,500	717,500
Number of Shares, RSU's Granted
Number of Shares, RSU's Vested		(310,000)
Number of Shares, RSU's Forfeited		(145,000)
Number of Shares, RSU's Outstanding Ending	262,500	262,500
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning	$ 0.59	$ 0.59
Weighted Average Grant Date Fair Value, RSU's Granted
Weighted Average Grant Date Fair Value, RSU's Vested
Weighted Average Grant Date Fair Value, RSU's Forfeited
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending	$ 0.59	$ 0.59

Legal Matters (Details Narrativ

Legal Matters (Details Narrative) - USD ($)	Dec. 16, 2019	Dec. 04, 2019	Nov. 25, 2019	Mar. 31, 2019	Dec. 31, 2018
Number of shares issued, value				$ 100,000	$ 738,140
Settlement Agreement [Member] \| Plaintiff [Member]
Number of shares issued, value			$ 500,000
Number of warrants issued			$ 500,000
Initial payment	$ 10,000	$ 33,503

Commitment (Details Narrative)

Commitment (Details Narrative) - Employment Agreement [Member] - Dr. Michael K. Korenko [Member]	Jun. 04, 2019USD ($)
Agreement term description	The employment term under the Employment Agreement commenced with an effective date of June 11, 2019 and expires on December 31, 2020, and December 31 of each successive year if the Employment Agreement is extended, unless terminated earlier as set forth in the Employment Agreement.
Compensation amount	$ 180,000
Compensation payable in monthly intervals	$ 120,000
Compensation payable description	Under the terms of the Employment Agreement, the Company shall pay to Dr. Korenko a base compensation of $180,000. Of this amount, $120,000 is booked in monthly intervals and the remaining balance is only paid upon the Company achieving a cash balance that exceeds $1,000,000. The Company has elected to record the compensation as $120,000, and upon achieving the milestone of $1,000,000 in cash balances, will record the deferred compensation at that time.

Concentrations of Credit and _2

Concentrations of Credit and Other Risks (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Allowance for bad debt expense
Customer One[Member]
Accounts receivable
Customer One[Member] \| Revenue [Member]
Concentration risk percentage	100.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 15, 2020	Feb. 20, 2019	Mar. 31, 2020	Jan. 31, 2020	Nov. 30, 2019	Jan. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Subsequent Event [Line Items]
Interest rate, percenatage		8.00%
Debt maturity date		Aug. 20, 2019
Number of shares issued					150,000,000
Number of shares issued, value							$ 100,000	$ 738,140
Convertible note payable								53,824	$ 465,618
Debt principal amount		$ 100,000
Accrued interest								$ 58,593	$ 75,166
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued						18,390,225
Series C Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares issued						821,292
Subsequent Event [Member]
Subsequent Event [Line Items]
Accrued interest			$ 23,427
Subsequent Event [Member] \| Convertible Note Agreements [Member]
Subsequent Event [Line Items]
Debt maturity date			Mar. 31, 2022
Number of warrants granted			2,075,000
Warrant exercise price			$ 0.045
Warrant term			2 years
Conversion of preferred stock into common stock, shares			87,686
Subsequent Event [Member] \| Regulation A Plus [Member]
Subsequent Event [Line Items]
Number of warrants granted			2,320,000
Warrant exercise price			$ 0.045
Warrant term			2 years
Number of shares issued			4,640,000
Number of shares issued, value			$ 125,280
Warrants purchase price			1,243
Subsequent Event [Member] \| Convertible and Non-Convertible Note [Member]
Subsequent Event [Line Items]
Interest rate, percenatage				12.50%
Debt maturity date				Jan. 15, 2020
Subsequent Event [Member] \| Note One [Member] \| Extended Maturity [Member]
Subsequent Event [Line Items]
Proceeds from issuance of convertible note	$ 50,000
Debt maturity date	Aug. 15, 2020
Subsequent Event [Member] \| Note Two [Member] \| Extended Maturity [Member]
Subsequent Event [Line Items]
Proceeds from issuance of convertible note	$ 50,000
Debt maturity date	Aug. 15, 2020
Subsequent Event [Member] \| Convertible Promissory Notes [Member]
Subsequent Event [Line Items]
Convertible note payable			526,113
Debt principal amount			415,000
Accrued interest			$ 23,427
Subsequent Event [Member] \| Warrant [Member] \| Convertible Note Agreements [Member]
Subsequent Event [Line Items]
Debt maturity date			Mar. 31, 2022
Number of warrants granted			4,400,000
Warrant exercise price			$ 0.045
Subsequent Event [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Conversion of preferred stock into common stock, shares				5,449,875
Subsequent Event [Member] \| Common Stock [Member] \| Convertible Note Agreements [Member]
Subsequent Event [Line Items]
Conversion of preferred stock into common stock, shares			19,485,668
Subsequent Event [Member] \| Accredited Investor [Member]
Subsequent Event [Line Items]
Proceeds from issuance of convertible note				$ 100,000
Interest rate, percenatage				8.00%
Debt maturity date				Mar. 31, 2020
Number of warrants granted				1,250,000
Warrant exercise price				$ 0.06
Warrant term				2 years
Subsequent Event [Member] \| Accredited Investor [Member] \| Warrant [Member]
Subsequent Event [Line Items]
Debt maturity date				Mar. 31, 2022
Number of warrants granted				1,312,500
Warrant exercise price			$ 0.06
Subsequent Event [Member] \| Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Payment to redemptiom of preferred stock				$ 50,000
Number of shares redeembale				100,000
Subsequent Event [Member] \| Series C Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of preferred stock into common stock, shares				435,990